EP1495117A2 - Human deubiquitinating protease gene on chromosome 7 and its murine ortholog - Google Patents

Abstract

Human and murine analogs of DUBs, hematopoietic-specific, cytokine-inducible deubiquitinating proteases, clustered on chromosome 7 and their respective regulatory regions are identified. The nucleotide or proteins encoded thereby may be used in assays to identify inhibitors of hDUB7 or mDUB7. The invention also includes transducing peptides comprising an NLS or transducing sequence of hDUB7 or mDUB7 linked to a cargo molecule, and methods of delivering a biologically active protein, therapeutically effective compound, antisense nucleotide, or test compound to a cell wherein a transducing peptide is added exogenously to a cell.

Description

HUMAN DEUBIQUITINATING PROTEASE GENE ON CHROMOSOME 7

AND ITS MURINE ORTHOLOG

5 Background of the Invention

The role of ubiquitin in protein degradation was discovered and the main enzymatic reactions of this system elucidated in biochemical studies in a cell-free system from reticulocytes. In this system, proteins are targeted for degradation by covalent ligation to

0 ubiquitin, a 76-amino-acid-residue protein. Briefly, ubiquitin-protein ligation requires the sequential action of three enzymes. The C-terminal Gly residue of ubiquitin is activated in an ATP -requiring step by a specific activating enzyme, El (Step 1). This step consists of .an intermediate formation of ubiquitin adenylate, with the release of PP;, followed by the binding of ubiquitin to a Cys residue of El in a thiolester linkage, with the release of AMP. Activated

5 ubiquitin is next transferred to an active site Cys residue of a ubiquitin-carrier protein, E2 (Step 2). h the third step catalyzed by a ubiquitin-protein ligase or E3 enzyme, ubiquitin is linked by its C-terminus in .an amide isopeptide linkage to an -amino group of the substrate protein's Lys residues (Step 3).

!0 Proteins ligated to polyubiquitin chains are usually degraded by the 26S proteasome complex that requires ATP hydrolysis for its action. The 26S proteasome is formed by an ATP-dependent assembly of a 20S proteasome, a complex that contains the protease catalytic sites, with 19S "cap" or regulatory complexes. The 19S complexes contain several ATPase subunits and other subunits that are presumably involved in the specific action of the 26S

-5 proteasome on ubiquitinylated proteins. The roles of ATP in the assembly of the 26S proteasome complex and in its proteolytic action are not understood. The action of the 26S proteasome presumably generates several types of products: free peptides, short peptides still linked to ubiquitin via their Lys residues, and polyubiquitin chains (Step 4). The latter two products .are converted to free and reusable ubiquitin by the action of ubiquitin-C-terminal 0 hydrolases or isopeptidases (Steps 5 and 6). Some isopeptidases may also disassemble certain ubiquitin-protein conjugates (Step 7) and thus prevent their proteolysis by the 26S proteasome. The latter type of isopeptidase action may have a correction function to salvage incorrectly ubiquitinylated proteins or may have a regulatory role. Short peptides formed by the above processes can be further degraded to free amino acids by cytosolic peptidases (Step 8).

Ubiquitin-mediated degradation of protein is involved in various biological processes. The selective and programmed degradation of cell-cycle regulatory proteins, such as cyclins, inhibitors of cyclin-dependent kinases, and anaphase inhibitors are essential events in cell- cycle progression. Cell growth and proliferation are further controlled by ubiquitin-mediated degradation of tumor suppressors, protoonco genes, and components of signal transduction systems. The rapid degradation of numerous transcriptional regulators is involved in a variety of signal transduction processes and responses to environmental cues. The ubiquitin system is clearly involved in endocytosis and down-regulation of receptors and transporters, as well as in the degradation of resident or abnormal proteins in the endoplasmic reticumm. There are strong indications for roles of the ubiquitin system in development and apoptosis, although the target proteins involved in these cases have not been identified. Dysfunction in several ubiquitin-mediated processes causes pathological conditions, including malignant transformation.

Our knowledge of different signals in proteins that mark them for ubiquitinylation is also limited. Recent reports indicate that many proteins are targeted for degradation by phosphorylation. It was observed previously that many rapidly degraded proteins contain PEST elements, regions enriched in Pro, Glu, Ser, andThr residues. More recently, it was pointed out that PEST elements are rich in S/TP sequences, which are minimum consensus phosphorylation sites for Cdks and some other protein kinases. Indeed, it now appears that in several (though certainly not all) instances, PEST elements contain phosphorylation sites necessary for degradation. Thus multiple phosphorylations within PEST elements are required for the ubiquitinylation and degradation of the yeast Gl cyclins Cln3 and Cln2, as well as the Gcn4 transcriptional activator. Other proteins, such as the mammalian Gl regulators cyclin E and cyclin Dl, are targeted for ubiquitinylation by phosphorylation at specific, single sites. In the case of the IkBα inhibitor of the NF-kB transcriptional regulator, phosphorylation at two specific sites, Ser-32 and Ser-36, is required for ubiquitin ligation. β-cateinin, which is targeted for ubiquitin-mediated degradation by phosphorylation, has a sequence motif similar to that of IkBα around these phosphorylation sites. However, the homology in phosphorylation patterns of these two proteins is not complete, because phosphorylation of other sites of β-catenin is also required for its degradation. Other proteins targeted for degradation by phosphorylation include the Cdk inhibitor Siclp and the STAT1 transcription factor. Though different patterns of phosphorylation target different proteins for degradation, a common feature appears to be that the initial regulatory event is carried out by a protein kinase, while the role of a ubiquitin ligase would be to recognize the phosphorylated form of the protein substrate. It further appears that different ubiquitin ligases recognize different phosphorylation patterns as well as additional motifs in the various protein substrates. However, the identity of such E3s is unknown, except for some PULC-type ubiquitin ligases that act on some phosphorylated cell-cycle regulators in the budding yeast. The multiplicity of signals that target proteins for ubiquitin-mediated degradation (and of ligases that have to recognize such signals) is underscored by observations that the phosphorylation of some proteins actually prevents their degradation. Thus the phosphorylation of the c-Mos protooncogene on Ser3 and the multiple phosphorylations of c-Fos and c-Jun protooncogenes at multiple sites by MAP kinases suppress their ubiquitinylation and degradation.

In addition to the families of enzymes involved in conjugation of ubiquitin, a very large family of deubiquitinating enzymes has recently been identified from various organisms. These enzymes have several possible functions. First, they may have peptidase activity and cleave the products of ubiquitin genes. Ubiquitin is encoded by two distinct classes of genes. One is a polyubiquitin gene, which encodes a linear polymer of ubiquitins linked through peptide bonds between the C-terminal Gly .and N-terminal Met of contiguous ubiquitin molecules. Each copy of ubiquitin must be released by precise cleavage of the peptide bond between Gly-76-Met-l of successive ubiquitin moieties. The other class of ubiquitin genes encodes ubiquitin C-terminal extension proteins, which are peptide bond fusions between the C-terminal Gly of ubiquitin and N-terminal Met of the extension protein. To date, the extensions described are ribosomal proteins consisting of 52 or 76-80 a ino acids. These ubiquitin fusion proteins are processed to yield ubiquitin and the corresponding C-terminal extension proteins. Second, deubiquitinating enzymes may have isopeptidase activities. When a target protein is degraded, deubiquitinating enzymes can cleave the polyubiquitin chain from the target protein or its remnants. The polyubiquitin chain must also be disassembled by deubiquitinating enzymes during or after proteolysis by the 26 S proteasome, regenerating free monomeric ubiquitin. In this way, deubiquitinating enzymes can facilitate the ability of the 26 S proteasome to degrade ubiquitinated proteins. Third, deubiquitinating enzymes may hydrolyze ester, thiolester, and amide linkages to the carboxyl group of Gly-76 of ubiquitin. Such nonfunctional linkages may arise from reactions between small intracellular compounds such as glutathione and the E1-, E2-, or E3 -ubiquitin thiolester intermediates. Fourth, deubiquitinating enzymes may compete with the conjugating system by removing ubiquitin from protein substrates, thereby rescuing them from degradation or any other function mediated by ubiquitination. Thus generation of ubiquitin by deubiquitinating enzymes from the linear polyubiquitin and ubiquitin fusion proteins and from the branched polyubiquitin ligated to proteins should be essential for maintaining a sufficient pool of free ubiquitin. Many deubiquitinating enzymes exist, suggesting that these deubiquitinating enzymes recognize distinct substrates and are therefore involved in specific cellular processes. Although there is recent evidence to support such specificity of these deubiquitinating enzymes, the structure- function relationships of these enzymes remain poorly studied.

Deubiquitinating enzymes can be divided broadly on the basis of sequence homology into two classes, the ubiquitin-specific processing protease (UBP or USP, also known as type 2 ubiquitin C-terminal hydrolase (type 2 UCH)) and the UCH, also known as type 1 UCH). UCH (type 1 UCH) enzymes hydrolyze primarily C-terminal esters and amides of ubiquitin but may also cleave ubiquitin gene products and disassemble polyubiquitin chains . They have in common a 210-amino acid catalytic domain, with four highly conserved blocks of sequences that identify these enzymes. They contain two very conserved motifs, the CYS and HIS boxes. Mutagenesis studies revealed that the two boxes play important roles in catalysis. Some UCH enzymes have significant C-terminal extensions. The functions of the C-terminal extensions are still unknown but appear to be involved in proper localization of the enzyme. The active site of these UCH enzymes contains a catalytic triad consisting of cysteine, histidine, and aspartate and utilizes a chemical mechanism similar to that of papain. The crystal structure of one of these, UCH-L3, has been solved at 1.8 A resolution. The enzyme comprises a central antiparallel β-sheet flanked on both sides by helices. The β-sheet and one of the helices are similar to those observed in the thiol protease cathepsin B. The similarity includes the three amino acid residues that comprise the active site, Cys⁹⁵, His¹⁶⁹, and Asp¹⁸⁴. The active site appears to fit the binding of ubiquitin that may anchor also at an additional site. The catalytic site in the free enzyme is masked by two different segments of the molecule that limit nonspecific hydrolysis .and must undergo conformational rearrangement after substrate binding. UBP (type 2 UCH) enzymes are capable of cleaving the ubiquitin gene products and disassembling polyubiquitin chains after hydrolysis. It appears that there is a core region of about 450 amino acids delimited by CYS and HIS boxes. Many of these isoforms have N- terminal extensions and a few have C-terminal extensions. In addition, there are variable sequences in the core region of many of the isoforms. The functions of these divergent sequences remain poorly characterized. Another interesting function of specific UBPs is the regulation of cell proliferation. It was observed that cytokines induced in T-cells specific deubiquitinating enzymes (DUBs), termed DUB-1 and DUB-2. DUB-1 is induced by stimulation of the cytokine receptors for IL-3, IL-5, and GM-CSF, suggesting a role in its induction for the β-common (betac) subunit of the interleukin receptors. Overexpression of a dominant negative mutant of JAK2 inhibits cytokine induction of DUB-1, suggesting that the regulation of the enzyme is part of the cell response to the JAK/STAT signal transduction pathway. Continued expression of DUB-1 arrests cells at Gi; therefore, the enzyme appears to regulate cellular growth via control of the Go-Gi transition. The catalytic conserved Cys residue of the enzyme is required for its activity. DUB-2 is induced by IL-2 as an immediate early (IE) gene that is down-regulated shortly after the initiation of stimulation. The function of this enzyme is also obscure. It may stimulate or inhibit the degradation of a critical cell-cycle regulator.

Cytokines, such as interleukin-2 (IL-2), activate intracellular signaling pathways via rapid tyrosine phosphorylation of their receptors, resulting in the activation of many genes involved in cell growth and survival. The deubiquitinating enzyme DUB-2 is induced in response to IL-2 .and is expressed in human T-cell lymphotropic virus-I (HTLV-1)- transformed T cells that exhibit constitutive activation of the IL-2 JAK/STAT (signal transducers and activators of transcription) pathway, and when expressed in BaF3 cells DUB- 2 markedly prolonged IL-2-induced STAT5 phosphorylation. Although DUB-2 does not enhance IL-2-mediated proliferation, when withdrawn from growth factor, cells expressing DUB-2 had sustained STAT5 phosphorylation and enhanced expression of IL-2-induced genes cis .and c-myc. DUB-2 expression markedly inhibited apoptosis induced by cytokine withdrawal allowing cells to survive. Therefore, DUB-2 has a role in enhancing signaling through the JAK/STAT pathway, prolonging lymphocyte survival, and, when constitutively expressed, may contribute to the activation of the JAK/STAT pathway observed in some transformed cells. (Migone, T.-S., et al., Blood. 2001;98:1935-1941). Protein ubiquitmation is an important regulator of cytokine-activated signal transduction pathways and hematopoietic cell growth. Protein ubiquitmation is controlled by the coordinate action of ubiquitin-conjugating enzymes and deubiquitinating enzymes. Recently a novel family of genes encoding growth-regulatory deubiquitinating enzymes (DUB-1 and DUB-2) has been identified. DUBs are immediate-early genes and are induced rapidly and transiently in response to cytokine stimuli. By means of polymerase chain reaction amplification with degenerate primers for the DUB-2 complementary DNA, 3 murine bacterial artificial chromosome (BAG) clones that contain D UB gene sequences were isolated. One BAC contained a novel DUB gene (DUB-2 A) with extensive homology to DUB-2. Like DUB- 1 and DUB-2, the DUB-2 A gene consists of 2 exons. The predicted DUB-2 A protein is highly related to other DUBs throughout the primary amino acid sequence, with a hypervariable region at its C-terminus. h vitro, DUB-2 A had functional deubiquitinating activity; mutation of its conserved amino acid residues abolished this activity. The 5' flanking sequence of the DUB-2 A gene has a hematopoietic-specific functional enhancer sequence. It is proposed that there are at least 3 members of the DUB subfamily (DUB-1, DUB-2, and DUB-2 A) and that different hematopoietic cytokines induce specific DUB genes, thereby initiating a cytokine- specific growth response. (Baek , K.-H., et al, Blood. 2001;98:636-642).

Protein ubiquitmation also serves regulatory functions in the cell that do not involve proteasome-mediated degradation. For example, Hicke and Riezman have recently demonstrated ligand-inducible ubiquitmation of the Ste2 receptor in yeast. Ubiquitmation of the Ste2 receptor triggers receptor endocytosis and receptor targeting to vacuoles, not proteasomes. Also, Chenet al. have demonstrated that activation of the IB kinase requires a rapid, inducible ubiquitmation event. This ubiquitmation event is a prerequisite for the specific phosphorylation of LB and does not result in subsequent proteolysis of the kinase complex. The ubiquitmation of Ste2 and IB kinase appears reversible, perhaps resulting from the action of a specific deubiquitinating enzyme.

A large superfamily of genes encoding deubiquitinating enzymes, or UBPs, has recently been identified. UBPs are ubiquitin-specific thiol-proteases that cleave either linear ubiquitin precursor proteins or post-translationally modified proteins containing isopeptide ubiquitin conjugates. The large number of UBPs suggests that protein ubiquitmation, like protein phosphorylation, is a highly reversible process that is regulated in the cell.

Interestingly, UBPs vary greatly in length and structural complexity, suggesting functional diversity. While there is little .amino acid sequence similarity throughout their coding region, sequence comparison reveals two conserved domains. The Cys domain contains a cysteine residue that serves as the active enzymatic nucleophile. The His domain contains a histidine residue that contributes to the enzyme's active site. More recent evidence demonstrates six homology domains contained by all members of the ubp superfamily. Mutagenesis of conserved residues in the Cys and His domains has identified several residues that are essential for UBP activity.

Recently, a growth regulatory deubiquitinating enzyme, DUB-1, that is rapidly induced in response to cytokine receptor stimulation was identified. DUB-1 is specifically induced by the receptors for IL-3, granulocyte macrophage-colony-stimulating factor, and IL-5, suggesting a specific role for the c subunit shared by these receptors. In the process of cloning the DUB-1 gene, a family of related, cross-hybridizing DUB genes was identified. From this, other DUB genes might be induced by different growth factors. Using this approach, an IL-2- inducible DUB enzyme, DUB-2 and closely related DUB-2a were identified. DUB-1 and DUB-2 are more related to each other than to other members of the ubp superfamily and thereby define a novel subfamily of deubiquitinating enzymes.

Hematopoietic-specific, cytokine induced DUBs in murine system have shown to prolong cytokine receptor, see Migone, T. S., et al. (2001). The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal, Blood 98, 1935-41; Zhu, Y., et al., (1997). DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes, J Biol Chem 272, 51-7 and Zhu, Y., et al., (1996). The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor, Mol Cell Biol 16, 4808- 17.). These effects are likely due to the deubiquitination of receptors or other signaling intermediates by DUB-1 or DUB-2, murine analogs of hDUBs. Inhibition of lDUBs may achieve downregulation of specific cytokine receptor signaling, thus modulating specific immune responses. Cytokines regulate cell growth by inducing the expression of specific target genes. A recently identified a cytokine-inducible, immediate-early gene, DUB-1, encodes a deubiquitinating enzyme with growth regulatory activity. In addition, a highly related gene, DUB-2, that is induced by interleukin-2 was identified. The DUB-2 mRNA was induced in T cells as an immediate-early gene and was rapidly down-regulated. Like DUB-1, the DUB-2 proteinhad deubiquitinating activity in vitro. When a conserved cysteine residue of DUB-2, required for ubiquitin-specific thiol protease activity, was mutated to serine (C60S), deubiquitinating activity was abolished. DUB-1 and DUB-2 proteins are highly related throughout their primary amino acid sequence except for a hypervariable region at their

COOH terminus. Moreover, the DUB genes co-localize to a region of mouse chromosome 7, suggesting that they arose by a tandem duplication of an ancestral DUB gene. Additional DUB genes co-localize to this region, suggesting a larger family of cytokine-inducible DUB enzymes. We propose that different cytokines induce specific DUB genes. Each induced DUB enzyme thereby regulates the degradation or the ubiquitmation state of an unknown growth regulatory factor, resulting in a cytokine-specific growth response. On the basis of these structural criteria, additional members of the DUB subfamily can be identified in the GenBank™. The highest degree of homology is in the Cys and His domains. Additionally, this putative human DUB protein contains a Lys domain (amino acids 400-410) and a hypervariable region (amino acids 413-442).

Murine DUB (mDUB) subfamily members differ from other UBPs by functional criteria as well. mDUB subfamily members are cytokine-inducible, immediate-early genes and may therefore play regulatory roles in cellular growth or differentiation. Also, DUB proteins are unstable and are rapidly degraded by ubiquitin-mediated proteolysis shortly after their induction.

mDUB reports demonstrate that specific cytokines, such as IL-2 and IL-3, induce specific deubiquitinating enzymes (DUBs). The DUB proteins may modify the ubiquitin- proteolytic pathway and thereby mediate specific cell growth or differentiation signals. These modifications are temporally regulated. The DUB-2 protein, for instance, is rapidly but tr-ansiently induced by IL-2. Interference of DUB enzymes with specific isopeptidase inhibitors may block specific cytokine signaling events. The prior art teaches some partial sequences with homology to DUBs; specifically Human cDNA sequence SEQ ID NO: 17168 in EP 1074617- A2; a human protease and protease inhibitor PP -4 encoding cDNA; in WO200110903-A2 and human ubiquitin protease 23431 coding sequence in WO200123589-A2.

References

1. Baek, K. H., Mondoux, M. A., Jaster, R., Fire-Levin, E., and D'Andrea, A. D. (2001). DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes, Blood 98, 636-42. 2. Jaster, R., Baek, K. H., and D'Andrea, A. D. (1999). Analysis of cis-acting sequences and transacting factors regulating the interleukin-3 response element of the DUB-1 gene, Biochim Biophys Acta 1446, 308-16.

3. Jaster, R., Zhu, Y., Pless, M., Bhattacharya, S., Mathey-Prevot, B., and D'Andrea, A. D. (1997). JAK2 is required for induction of the murine DUB-1 gene, Mol Cell Biol 17, 3364-72. 4. Migone, T. S., Humbert, M., Rascle, A., Sanden, D., D'Andrea, A., Johnston, J. A., Baek, K. H., Mondoux, M. A., Jaster, R., Fire-Levin, E., et al. (2001). The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal, Blood 98, 1935-41.

5. Zhu, Y., Carroll, M., Papa, F. R., Hochstrasser, M., and D'Andrea, A. D. (1996a). DUB-1, a deubiquitinating enzyme with growth-suppressing activity, Proc Natl Acad Sci U S A 93, 3275-9.

6. Zhu, Y., Lambert, K., Corless, C, Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and D'Andrea, A. D. (1997). DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes, J Biol Chem 272, 51-7.

7. Zhu, Y., Pless, M., Jnhorn, R., Mathey-Prevot, B., and D'Andrea, A. D. (1996b). The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor, Mol Cell Biol 16, 4808-17.

Scott Emr described a role for monoubiquitination in protein sorting in the late endosome, which has a role in determining which proteins, both newly synthesized and endocytosed, will be delivered to the lumen of the vacuole and which to its limiting membrane. Proteins destined for lumen .are sorted into internal vesicles at the multivesicular body (MNB) stage of endosome maturation, whereas proteins destined for the vacuolar membrane, or for recycling to the plasma membrane, remain in the endosome's limiting membrane. Emr showed that the sorting of a vacuolar hydrolase into MNB vesicles requires the monoubiqutination of this cargo molecule at a specific lysine residue (Katzmann et al, 2001). Thus, monoubiquitination is a green light for traffic to proceed from this important intracellular intersection to the lumen of the vacuole. The policeman directing the traffic is an endosome-localized protein complex called ESCRT-I, one of whose components, Nps23, plays a key role in recognizing the cargo's ubiquitin signal (Katzmann et al., 2001). Nps23 is one of a small family of UEV proteins (ubiquitin E2 variants) that resemble E2s but cannot perform canonical E2 functions. The ESCRT-I complex binds ubiquitin, .and a mutation in Nps23 that cripples ubiquitin-dependent sorting in the MNB pathway abolishes ubiquitin binding to ESCRT-I. A model in which Nsp23 binds ubiquitin directly, while still inferential, received support from structural studies of a different UEN protein. Intriguingly, the mammalian homolog of Nps23, known as tsglOl, is a tumor suppressor (Li and Cohen, 1996) The current results suggest that mutations in ) tsglOl could cause persistent signaling by growth factor receptors because of inappropriate receptor recycling to the plasma membrane, thus leading to tumorigenesis.

A role for monoubiquitination in triggering the first step of endocytosis — the internalization of plasma membrane proteins — is well established (Hicke, 2001), but how this signal is

5 recognized has been unclear. Linda Hicke reported that yeast Entl is vital for the ubiquitin- dependent endocytosis of yeast factor receptor (see also Wendland et al., 1999). Entl carries a proposed ubiquitin binding motif called the UDVI domain (Hofmann and Falquet, 2001 ), and Hicke showed that Entl indeed binds ubiquitin directly. Entl also binds clathrin (Wendland et al., 1999) and so is poised to link monoubiquitinated cargo molecules to the endocytic

0 machinery. Hicke's and Emr's results suggest that the ability of monoubiquitin to signal two different trafficking outcomes relies in part on distinct localizations of the relevant signal- recognizing components — Entl resides at the plasma membrane, while ESCRT-I is associated with late endosomes.

\5 Fanconi Anemia (FA) is a rare cancer susceptibility disorder associated with cellular sensitivity to DΝA damage that can be caused by mutations in at least seven genes. Alan D'Andrea shed new light on the molecular basis of FA: monoubiquitination of a specific lysine residue in one FA protein, known as D2, requires the activities of four upstream FA genes and leads to the relocalization of D2 within the nucleus (Garcia-Higuera et al., 2001 ). 0 In normal cells, monoubiquitination of D2 is strongly augmented following DΝA damage and is strictly required for damage-associated targeting of D2 and BRCA1 to subnucle.ar foci. Thus, D2 monoubiquitination links an FA protein complex to the BRCA1 repair machinery. Although the downstream events in this pathway are still unclear, localization of the signal- recognizing factor(s) will likely be critical. This new function of ubiquitin carries a strong flavor of certain roles of Sumo- 1, a UbL that has been implicated in protein targeting to specific subnuclear structures (Hochstrasser, 2000).

Polyubiquitin chains are well known as a signal for substrate destruction by 26S proteasomes. But there are several kinds of chains, linked through different lysines of ubiquitin, suggesting that different chains might be distinct signals (Pickart, 2000). James Chen provided rigorous proof of this hypothesis by showing that noncanonical polyubiuqitination can activate phosphorylation — in contrast to numerous examples of the converse regulation (Hershko and Ciechanover, 1998). Postreplicative DNA repair and the activation of IkBα kinase (IKK) require chains linked through Lys63, rather than the Lys48-chains that usually signal proteasomal proteolysis. Chen found that Takl kinase is a downstream target of Lys63-chain signaling in the IKK activation pathway. The assembly of these chains depends on an unusual UEV/E2 complex and a RING finger protein, Traf6 (Deng et al., 2000). (The RING finger defines a large E3 family.) Modification of Traf6 with a Lys63 -chain leads to the activation of Takl, which in turn phosphorylates IKK (Wang et al., 2001). Activated IKK then phosphorylates IkBα and triggers its tagging with Lys48-chains. Only then do proteasomes enter the picture — they degrade IkBα and thereby free its partner, NFkB, to translocate to the nucleus and activate the expression of inflammatory response genes. Chen's results suggest that Traf6 is the target of the Lys63 -chain, as well as a catalyst of its assembly. Indeed, many other RING E3s also self-modify — although the consequence is more apt to be suicide (cf. tagging with Lys48-chains) than the kind of personality change seen with Traf6 (Joazeiro and Weissman, 2000). It remains to be seen if a similar mechanism applies in DNA repair, where a different RING protein, the Rad5 helicase, binds to a related UEV/E2 complex (Ulrich and Jentsch, 2000). New genetic data reported by Helle Ulrich confirmed the central importance of Rad5 in Lys-63 chain signaling in DNA repair (Ulrich, 2001).

These reports suggest a variety of new functions of protein ubiquitination and its potential involvement of subcellular trafficking including nucleus and the lumen of the intracellular vesicles. Thus regulation of ubiquitination by deubiquitinating proteases in various subcellular localization is become a critical issue. Recently, a number of proteins have been identified as capable of transducing, that is, moving across cellular and nuclear membranes in an energy-independent manner. Transducing sequences have been identified in proteins involved in circadian rhythm, such as human Period proteins. It is thought that these proteins move more freely through cellular and nuclear membranes, and that this movement permits concerted control. No other enzymes involved in the deubiquitination activities have been identified as being capable of transducing or having NLS until now.

The presence of an NLS at the C-terminal suggests that the hDUB7 .and its murine ortholog, mDUB7, are capable of translocating to the nucleus, possibly by importin-dependent manner and that these DUBs have a role in deubiquitinating ubiquitinated nuclear proteins and/or ubiquitinated proteins that are translocated to the nucleus. This has never been identified before. Protein ubiquitination targets selectively to proteasome degradation and/or provides facilitating protein localization. Thus, nuclear protein deubiquitination may have a role in unique function in regulation of nuclearprotein degradation as well as nuclear protein localization. The same logic can be applied to the vesicular targeting of DUB7 by targeting sequence, regulating vesicular protein degradation as well as invloved in traficking of vesicular proteins.

References

Katzmann D.J., Babst M. and Emr S.D. (2001) Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell, 106:145-155.

Li L. and Cohen S.N. (1996) tsglOl: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell, 85 :319-329.

Hicke L. (2001) A new ticket for entry into budding vesicles — ubiquitin. Cell, 106:527-530.

Wendland B., Steece K.E. and Emr S.D. (1999) Yeast epsins contain an essential N-terminal

ENTH domain, bind clathrin, and are required for endocytosis. EMBO J., 18:4383-4393.

Hofmann K. and Falquet L. (2001) A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends Biochem. Sci., 26:347-

350. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C, Hejna J., Grompe M. and D'Andrea A.D. (2001) Interaction of the Fanconi Anemia proteins and BRCA1 in a common pathway. Mol. Cell, 7:249-262.

Hochstrasser M. (2000) Evolution and function of ubiquitin-like protein-conjugation systems. Nat. Cell Biol., 2-.Ε153-E157.

Pickart CM. (2000) Ubiquitin in chains. Trends Biochem. Sci., 25:544-548.

Pickart CM. (2000) Ubiquitin in chains. Trends Biochem. Sci, 25:544-548.

Hershko A. and Ciechanover A. (1998) The ubiquitin system. Annu. Rev. Biochem., 67:425-

479. Deng L., Wang C, Spencer E., Yang L., Braun A., You J., Slaughter C, Pickart C. and Chen

Z.J. (2000) Activation of the JJ B kinase complex by TRAF6 requires a dimeric ubiquitin- conjugating enzyme complex and a unique polyubiquitin chain. Cell, 103:351-361.

Wang C, Deng L., Hong M., Akkaraju G.R., hioue J.-I. and Chen Z.J. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 412:346-351. Joazeiro C.A.P. and Weissman A.M. (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell, 102:549-552.

Ulrich H. (2001) The srs2 suppressor of UN sensitivity acts specifically on the RAD5- and S2-dependent branch of the RAD6 pathway. Nucleic Acids Res., 29:3487-3494.

Ulrich H.D. and Jentsch S. (2000) Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair. EMBO J., 19:3388-3397.

Summary of the Invention

The present invention is directed to identification of human homolog of murine DUBs, hematopoietic-specific, cytokine-inducible deubiquitinating proteases found on chromosome 7, respective regulatory region and its murine ortholog, n-amed as hDUB7 and mDUB7, respectively. Both hDUB7 and its murine ortholog mDUB7 were identified by searching human and mouse genome databases using murine DUB-1 and DUB-2 sequences. These genes (hDUB7 and mDUB7) share open reading frames (ORFs) that are 67% amino acid identity to each other, when gaps caused by deletion was not counted as mismatch, and exhibit 15% identity in nucleotide sequence. Furthermore, both hDUB7 and mDUB7 share 48% identity to murine DUBs, DUB1 and DUB2 within 297 amino acids core DUB sequences. In addition, hDUB7 and mDUB7 genes share open reading frames that are greater than 92%o amino acid identity within 540 amino acids N-terminal ubiquitin protease domain (with 98.4%o identity within 313 amino acid core). These genes also exhibit 74% identity within 138 amino acids C-teraiinal conserved domain containing several putative nuclear localization sequences (NLSs) and stretchs of amino acid sequences that is known to possess transducing capacity (K-AKKm XSKKKKKSKDKHR and HRHKKKKKKKKRHSRK). Therefore, the present invention is also directed to a transducing peptide comprising an NLS or transducing sequence of l DUB7 or mDUB7 linked to a cargo molecule. The invention also includes a transducing peptide comprsing an NLS or transducing sequence is selected from the group consisting of a peptidyl fragment comprising KLAKKHKKSKKK-KKSKDKHR, HRHKKKKKKKKRHSRK, KKHKKSKKKKKSKDKHR, and H RKKKKKKKRHSRK. The invention also comprsises a transducing peptide wherein the cargo molecule is a biologically active protein, therapeutically effective compound, antisense nucleotide, or test compound. The invention also includes a method of delivering a biologically active protein, therapeutically effective compound, antisense nucleotide, or test compound to a cell wherein a transducing peptide is added exogenously to a cell.

Manipulation of these gene products by small molecular compounds can (1) reduce inflammation by regulating proinflammatory cytokine signaling, (2) modulate autoimmune diseases by regulating cytokine receptor signaling that are critical for lymphocytes proliferation, and (3) immune over-reaction during infection using above mechanisms.

Search methods for identifying hPUB7 .and mDUB7: mDUBl (U41636), mDUB2 (U70368), and mDUB2A (AF393637) DNA sequences were used to search against nr (All non-redundant GenBank CDS translations+PDB+SwissProt+PIR+PRF) in GenBank for potential homologs. Homology was found to a cDNA (AK022759) whose C terminal was incomplete (3660 nucleotides capable of expressing 1197 amino acids run-off translation), hi order to in silico clone the full length.

Both EST extending and genomic sequence annotation methods were used. Sequence of

AK022759 was searched against human ESTs and genomic sequences. AK022759 was extended manually based on matching ESTs and mapped genomic sequence on contig NT_007844.8 from cliromosome 7. From these full-length sequence for open reading frame for hDUB7 was generated (3951 nucleotides long DNA segment capable of generating 1316 amino acids long polypeptide). For in silico cloning of the putative full length of mDUB7, hDUB7 amino acid sequence was used to search against nr by blastp. The highest match to Mouse proteins is a protein similar to mDUB2. The accession number for this protein is BAB27190 and for nucleotide sequence is AK010801 (1485 nucleotide long capable of translating 487 amino acids run-on translation). Based on Genbank annotation, the gene has partial sequence with C terminal incomplete, hi order to get the full length of mDUB7, nucleotide sequence of AK010801 was used to search against Mouse Genomic sequence. There was no match to Mouse curated NT contigs database and match was found on contig_70795 from Mouse Arachne_Nov30 database (preliminary assembly of the mouse WGS reads based on an Nov 9th freeze of the WGS data) in Genbank. Putative genes from contig_70795 were annotated by GENSCAN prediction. There is one putative protein with extended/finished C terminal aligned perfectly with BAB27190 except having 33 amino acids missing in the middle of sequence. The nucleotide sequence of the 33 amino acids segment from BAB27190 was searched against the Mouse genomic sequence and found it matched to the genomic sequence region that generates the putative full length mDUB7 and has potential splice sites on the borders. It implies that exon was missed by GENSCAN annotation. A full length mouse DUB7 was constructed by adding 33 amino acids to the putative protein according to the genomic sequence alignment (3981 nucleotides long open reading frame capable of generating 1326 amino acids long polypeptide). The final mDUB7 sequence was aligned with hDUB7 and showed 67%> homology in amino acid level and 75%> homology in nucleotide level.

TaqMan real time PCR analysis of expression ofhDUB7 in human immunocytes upon various stimulation

Protocol of reverse transcription (RT) from total cellular RNA using random hexamer as primer (using TaqMan Reverse Transcription Reagents Cat# N808-0234)

1 ug of total RNA preparation in 100 ul of lxTaqMan RT Buffer Mix, 5.5mM MgCl₂ , 0.5 mM dNTPs, 2.5 uM Random Hexamers, 40 U RNAse inhibitor, 125U Multiscribe Reverse Transcriptase. Mix by pipeting up and down. Incubate 25°C for 10 minutes (annealing step), 48°C for 30 minutes (reverse transcription), and 95°C for 5 minutes (heat killing of the enzyme). The samples can be left at the machine at 4°C, or alternatively, can be stored at - 20°C Yield of cDNA synthesis can be measured by incorporation of small portion of radioactive dATP (or dCTP). Average efficiency for this protocol is between 60-80% of conversion of RNA to cDNA.

Protocol of TaqMan real-time quantitative PCR

1 ul of TaqMan RT product in 12.5 ul of lx master Mix (Applied Biosystems Cat# 4304437)containing all necessary reaction components except primers and probes, 0.9 uM forward primer , 0.9 uM reverse primer, 0.2 uM probe. Mix by pipetting up and down. Samples containing GADPH primer pair and probe were also prepared as control. Thermal cycling and detection of the real-time amplification were performed using the ABI PRISM 7900HT Sequuence Detection System. The quantity of target gene is given relative to the GADPH control based on C_t values determined during the exponential phase of PCR.

Primer-probe set used is as follow:

Forward Primer 5 '-CCACGACAGAACTGCACTTGTAG-3 ' Reverse Primer 5'- CCGGGACTTTCCATTTTCG-3' Probe sequence 5'- CAACTGTAACCTCTCTGATCGGTTTCACGAA-3'

Table 1. Expression of hDUB7 in PBMC stimulated with LPS (100 ng/ml) for 1.5, 7and 24 hours by TaqMan (Donor 1).

Table 2. Expression of DUB7 in PBMC stimulated with LPS (100 ng/ml) and/or PHA (5 ug/ml) for 1.5, 7, 24 hours by TaqMan (donor 2, donor 3)

Table 3. Expression of hDUB7 in enriched B cells stimulated with LPS (100 ng/ml) or IL-4 and anti-CD40 mAb for 4 and 20 hours by TaqMan (Donor 4).

Table 4. Expression of hDUB7 in entiched CD4⁺ T cells stimulated with anti-CD3 and anti- CD28 mAbs for 3,6 and 18 hours by TaqMan (Donor 5).

Table 5. Expression of hDUB7 in differentiated ThO, Thl and Th2 CD4⁺ T cells (Day 4 after differentiation) stimulated with anti-CD3 .and ,anti-CD28 mAbs for 8 hours by TaqMan (Donor 6).

Table 6. Expression of hDUB7 in differentiated ThO, Thl and Th2 CD4⁺ T cells (Day 7 after differentiation) stimulated with anti-CD3 and anti-CD28 mAbs for 8 and 18 hours by TaqMan (Donor 6).

Table 7. Expression of hDUB7 in various tissue examined by Affymatrix chip analysis

Tissue Relative Intensity

Con_Adipose_l 2287

Con_Adipose_2 4190

CN_Heart_l 2545

CV_Heart_2 3907

CN_Heart_3 5367

CN_Pericardia_l 3682

Dig_Colon_l 2387

Dig_Colon_2 2894

Dig_Esophagus_l 5004

Dig_Esophagus_2 1658 Dig_FetalLiver_l 1288

Dig_FetalLiver_2 4676

Dig_FetalLiver_3 829

Dig_FetalLiver_4 3161

Dig_Liver_l 3094

Dig_Liver_2 1527

Dig_Liver_3 3410

Dig_Pancreas_l 3731

Dig_Pancreas_2 4837

Dig_Rectum_l 2329

Dig_Rectum_2 1851

Dig_SalivaryGland_l 2337

Dig_S alivaryGland_2 2110

Dig_SmallIntestine_l 2838

Dig_SmallIntestine_2 2662

Dig_Stomach_l 2187

End_AdrenalGland_ l 591

End_AdrenalGland__2 2199

End_Thyroid_l 2564

End_Thyroid_2 2392

End_Thyroid_3 3522

Exo_Breast_l 3673

Exo_Breast_2 6173

Exo MammaryGland 3741

_1 hnm_BoneMarrow_l 1090 hnm_Spleen_l 2429

Imm_Thymus_l 3666

Imm_Thymus_2 1759

Rep_Cervix_l 4482

Rep_Cervix_2 3362

Rep_Placenta_l 1248

Rep_Placenta_2 2378

Rep_Placenta_3 1622

Rep_Prostate_l 5128

Rep_Prostate_2 2762

Rep_Testis_l 2252

Rep_Testis_2 3196

Reρ_Uterus_l 4720

Rep_Uterus_2 3789

Res_Lung_l 2313

Res_Lung_2 3177

Res_Lung_3 4409

Res_Lung_4 2366

Res_Trachea_l 2152

Res_Trachea_2 2358

Res_Trachea_3 812

Res_Trachea_4 812

Sk_SkeletalMuscle_l 2838

Sk SkeletalMuscle 2 6106 Skin_Skin_l 5500

Uri_Kidney_l 3593

Uri_Kidney_2 1311

Uri_Kidney_3 2747

Uri_Kidney_4 1530

NS_Brain_l 3214

NS_Brain_2 2173

NS_Brain_3 1332

NS_Brain_4 2604

NS Brain 5 1663

NS_Cerebellum_l 3175

NS_Cerebellum_2 1766

NS_FetalBrain_l 4299

NS_FetalBrain_2 2549

NS_FetalBrain_3 4027

NS SpinalCord 1 2976

NS SpinalCord 2 3999

NS SpinalCord 3 4614

Table 8. Expression of mDUB7 in various tissue examined by Affymatrix chip analysis Mouse # Organ Relative Intentisty

A stomach 56

A stomach 11

B stomach 175

B stomach 97

C stomach 178

C stomach 126

A lymph 516

A lymph 365

B lymph 494

B lymph 335

C lymph 475

C lymph 509

A thymus 913

A thymus 1015

B thymus 881

B thymus 927

C thymus 834

C thymus 975

A prostate 327

A prostate 350

B prostate 75

B prostate 423

C prostate 405

C prostate 267

A uterus 549

A uterus 372

B uterus 225

B uterus 418 C uterus 335

C uterus 401

Deubiquitination Assay

Confirmation that the DUB is a deubiquitinating enzyme may be shown using previously identified deubiquitination assay of ubiquitin—galactosidase fusion proteins, as described previously in the literature. Briefly, a fragment of the DUB, of approximately 1,500 nucleotides, based on the wild-type DUB cDNA (corresponding to amino acids 1 to about 500) and a cDNA containing a missense mutation are generated by PCR and inserted, in frame, into pGEX (Pharmacia), downstream of the glutathione S-transferase (GST) coding element. Ub-Met~gal is expressed from a pACYC184-based plasmid. Plasmids are co- transformed as indicated into MCI 061 Escherichia coli. Plasmid-bearing E. coli MCI 061 cells are lysed and analyzed by immunoblotting with a rabbit anti~gal antiserum (Cappel), a rabbit anti-GST antiserum (Santa Cruz), and the ECL system (Amersham Corp.). in vitro deubiquitinating enzyme activity may be shown from purified hDUB fusion protein using commercial polyubiquitinated protein as substrate.

HDUB7 and mDUB7 are potential inflamatory cytokins specific Immediate-early Genes mDUB-1 was originally cloned as an IL-3 -inducible immediate-early gene. Similarly, mDUB-2 was cloned as an IL-2-inducible immediate-early gene. We examined inducibility as well as cell-type specific expression of these genes using Affymatrix-Chip analysis and multiple TaqMan analysis from human organ RNA samples and human immunocytes RNA samples. Our data suggest that expression of hDUB7 are not apparent in monoocytes and other myoloid cell types but high in fresh human PBMC from several donor. Furthermore, enriched cell populations of several lymphocytes, including B cells, CD4+ T cells of Th-1 and Th-2 differentiation conditions as well as bulk CD4+ T cells showed significant upregulation upon appropriate stimulations. Currently, we can not rule out the possibility of upregulation upon stimulation in CD8+ T cells and potentially NK/NK-T cells.

The DUB Subfamily of the ubp Superfamily From these data we propose that hDUB4s and hDUB8s are members of a discrete subfamily of deubiquitinating enzymes that shows the strongest similarity to mDUB subfamily including mDUBl, mDUB2, and mDUB2A, called the DUB subfamily. D UB subfamily members contain distinct structural features that distinguish them from other ubps. First, DUB subfamily members are comparatively small enzymes of approximately 500-550 amino acids. Second, DUB subfamily members share amino acid similarity not only in the Cys and His domains but also throughout their primary amino acid sequence. For instance, DUB proteins contain a lysine-rich region (Lys domain) and a HN domain near their carboxyl terminus.

The regulatory regions, or promoter regions, of each of the hDUB7 was analyzed for putative transcription factor binding motifs using TRAΝSFACFind, a dynamic programming method, see Heinemeyer, T., et al., "Expanding the TRAΝSFAC database towards an expert system of regulatory molecular mechamsms" Nucleic Acids Res. 27, 318-322, (1999). The Transfac database provides eukaryotic cis- and trans-acting regulatory elements. The data is shown as table X.

Table 9, putative transcription factor binding motifs within the hDUB7 regulatory or promoter region. The position is indicated by nucleotides used in the table 9.

Table 10. Nucleotide sequence of coding region of human DUB7 (hDUB7)

ATGACCATAGTTGACAAAGCTTCTGAATCTTCAGACCCATCAGCCTATCAGAATC AGCCTGGCAGCTCCGAGGCAGTCTCACCTGGAGACATGGATGCAGGTTCTGCCAG CTGGGGTGCTGTGTCTTCATTGAATGATGTGTCAAATCACACACTTTCTTTAGGAC CAGTACCTGGTGCTGTAGTTTATTCGAGTTCATCTGTACCTGATAAATCAAAACCA TCACCACAAAAGGATCAAGCCCTAGGTGATGGCATCGCTCCTCCACAGAAAGTTC TTTTCCCATCTGAGAAGATTTGTCTTAAGTGGCAACAAACTCATAGAGTTGGAGCT GGGCTCCAGAATTTGGGCAATACCTGTTTTGCCAATGCAGCACTGCAGTGTTTAA CCTACACACCACCTCTTGCCAATTACATGCTATCACATGAACACTCCAAAACATGT CATGCAGAAGGCTTTTGTATGATGTGTACAATGCAAGCACATATTACCCAGGCAC TCAGTAATCCTGGGGACGTTATTAAACCAATGTTTGTCATCAATGAGATGCGGCG TATAGCTAGGCACTTCCGTTTTGGAAACCAAGAAGATGCCCATGAATTCCTTCAA TACACTGTTGATGCTATGCAGAAAGCATGCTTGAATGGCAGCAATAAATTAGACA GACACACCCAGGCCACCACTCTTGTTTGTCAGATATTTGGAGGATACCTAAGATC TAGAGTCAAATGTTTAAATTGCAAGGGCGTTTCAGATACTTTTGATCCATATCTTG ATATAACATTGGAGATAAAGGCTGCTCAGAGTGTCAACAAGGCATTGGAGCAGTT TGTGAAGCCGGAACAGCTTGATGGAGAAAACTCGTACAAGTGCAGCAAGTGTAA AAAGATGGTTCCAGCTTCAAAGAGGTTCACTATCCATAGATCCTCTAATGTTCTTA CACTTTCTCTGAAACGTTTTGCAAATTTTACCGGTGGAAAAATTGCTAAGGATGTG AAATACCCTGAGTATCTTGATATTCGGCCATATATGTCTCAACCCAACGGAGAGC CAATTGTCTACGTCTTGTATGCAGTGCTGGTCCACACTGGTTTTAATTGCCATGCT GGCCATTACTTCTGCTACATAAAAGCTAGCAATGGCCTCTGGTATCAAATGAATG ACTCCATTGTATCTACCAGTGATATTAGATCGGTACTCAGCCAACAAGCCTATGTG CTCTTTTATATCAGGTCCCATGATGTGAAAAATGGAGGTGAACTTACTCATCCCAC CCATAGCCCCGGCCAGTCCTCTCCCCGCCCCGTCATCAGTCAGCGGGTTGTCACCA ACAAACAGGCTGCGCCAGGCTTTATCGGACCACAGCTTCCCTCTCACATGATAAA GAATCCACCTCACTTAAATGGGACTGGACCATTGAAAGACACGCCAAGCAGTTCC ATGTCGAGTCCTAACGGGAATTCCAGTGTCAACAGGGCTAGTCCTGTTAATGCTT CAGCTTCTGTCCAAAACTGGTCAGTTAATAGGTCCTCAGTGATCCCAGAACATCCT AAGAAACAAAAAATTACAATCAGTATTCACAACAAGTTGCCTGTTCGCCAGTGTC AGTCTCAACCTAACCTTCATAGTAATTCTTTGGAGAACCCTACCAAGCCCGTTCCC TCTTCTACCATTACCAATTCTGCAGTACAGTCTACCTCGAACGCATCTACGATGTC AGTTTCTAGTAAAGTAACAAAACCGATCCCCCGCAGTGAATCCTGCTCCCAGCCC GTGATGAATGGCAAATCCAAGCTGAACTCCAGCGTGCTGGTGCCCTATGGCGCCG AGTCCTCTGAGGACTCTGACGAGGAGTCAAAGGGGCTGGGCAAGGAGAATGGGA TTGGTACGATTGTGAGCTCCCACTCTCCCGGCCAAGATGCCGAAGATGAGGAGGC CACTCCGCACGAGCTTCAAGAACCCATGACCCTAAACGGTGCTAATAGTGCAGAC AGCGACAGTGACCCGAAAGAAAACGGCCTAGCGCCTGATGGTGCCAGCTGCCAA GGCCAGCCTGCCCTGCACTCAGAAAATCCCTTTGCTAAGGCAAACGGTCTTCCTG GAAAGTTGATGCCTGCTCCTTTGCTGTCTCTCCCAGAAGACAAAATCTTAGAGAC CTTCAGGCTTAGCAACAAACTGAAAGGCTCGACGGATGAAATGAGTGCACCTGG AGCAGAGAGGGGCCCTCCCGAGGACCGCGACGCCGAGCCTCAGCCTGGCAGCCC CGCCGCCGAATCCCTGGAGGAGCCAGATGCGGCCGCCGGCCTCAGCAGCACCAA GAAGGCTCCGCCGCCCCGCGATCCCGGCACCCCCGCTACCAAAGAAGGCGCCTGG GAGGCCATGGCCGTCGCCCCCGAGGAGCCTCCGCCCAGCGCCGGCGAGGACATC GTGGGGGACACAGCACCCCCTGACCTGTGTGATCCCGGGAGCTTAACAGGCGATG CGAGCCCGTTGTCCCAGGACGCAAAGGGGATGATCGCGGAGGGCCCGCGGGACT CGGCGTTGGCGGAAGCCCCGGAAGGGTTGAGTCCGGCTCCGCCTGCGCGGTCGGA GGAGCCCTGCGAGCAGCCACTCCTTGTTCACCCCAGCGGGGACCACGCCCGGGAC GCTCAGGACCCATCCCAGAGCTTGGGCGCACCCGAGGCCGCAGAGCGGCCGCCA GCTCCTGTGCTGGACATGGCCCCGGCCGGTCACCCGGAAGGGGACGCTGAGCCTA GCCCCGGCGAGAGGGTCGAGGACGCCGCGGCGCCGAAAGCCCCAGGCCCTTCCC CAGCGAAGGAGAAAATCGGCAGCCTCAGAAAGGTGGACCGAGGCCACTACCGCA GCCGGAGAGAGCGCTCGTCCAGCGGGGAGCCCGCCAGAGAGAGCAGGAGCAAG ACTGAGGGCCACCGTCACCGGCGGCGCCGCACCTGCCCCCGGGAGCGCGACCGC CAGGACCGCCACGCCCCGGAGCACCACCCCGGCCACGGCGACAGGCTCAGCCCT GGCGAGCGCCGCTCTCTGGGCAGGTGCAGTCACCACCACTCCCGACACCGGAGCG GGGTGGAGCTGGACTGGGTCAGACACCACTACACCGAGGGCGAGCGTGGCTGGG GCCGGGAGAAGTTCTACCCCGACAGGCCGCGCTGGGACAGGTGCCGGTACTACC ATGACAGGTACGCCCTGTACGCTGCCCGGGACTGGAAGCCCTTCCACGGCGGCCG CGAGCACGAGCGGGCCGGGCTGCACGAGCGGCCGCACAAGGACCACAACCGGGG CCGTAGGGGCTGCGAGCCGGCCCGGGAGAGGGAGCGGCACCGCCCCAGCAGCCC CCGCGCAGGCGCGCCCCACGCCCTCGCCCCGCACCCCGACCGCTTCTCCCACGAC AGAACTGCACTTGTAGCCGGAGACAACTGTAACCTCTCTGATCGGTTTCACGAAC ACGAAAATGGAAAGTCCCGGAAACGGAGACACGACAGTGTGGAGAACAGTGACA GTCATGTTGAAAAGAAAGCCCGGAGGAGCGAACAGAAGGATCCTCTAGAAGAGC CTAAAGCAAAGAAGCACAAAAAATCAAAGAAGAAAAAGAAATCCAAAGACAAA CACCGAGACCGCGACTCCAGGCATCAGCAGGACTCAGACCTCTCAGCAGCGTGCT CTGACGCTGACCTCCACAGACACAAAAAAAAGAAGAAGAAAAAGAAGAGACATT CAAGAAAATCAGAGGACTTTGTTAAAGATTCAGAACTGCACTTACCCAGGGTCAC CAGCTTGGAGACTGTCGCCCAGTTCCGGAGAGCCCAGGGTGGCTTTCCTCTCTCTG GTGGCCCGCCTCTGGAAGGCGTCGGACCTTTCCGTGAGAAAACGAAACACTTACG GATGGAAAGCAGGGATGACAGGTGTCGTCTCTTTGAGTATGGCCAGGGTGATTGA

Table 11. Deduced amino acid sequence of coding region of hDUB7

C-terminal potential nuclear localization (as well as targeting) sequences are underlined.

MTINDKASESSDPSAYQNQPGSSEANSPGDMDAGSASWGAVSSLNDNSNΗTLSLGPN

PGANNYSSSSNPDKSKPSPQKDQALGDGIAPPQKNLFPSEKICLKWQQTHRNGAGLQ

ΝLGΝTCFAΝAALQCLTYTPPLAΝYMLSHEHSKTCHAEGFCMMCTMQAHITQALSΝP GDNIKPMFVIΝEMRRIA-RHFRFGΝQEDAHEFLQYTNDAMQKACLΝGSΝKLDRHTQA TTLNCQIFGGYLRSRNKCLΝCKGNSDTFDPYLDITLE-KAAQSVΝKALEQFNKPEQLD GEΝSYXCSKCKKMNPASKRFTIHRSSΝNLTLSLI IFAΝFTGGKIA-KDNKYPEYLD-RP YVISQPΝGEP YNLYANLNHTGFΝCFIAGHYFCYIKASΝGLWYQMΝDSINSTSDIRSN LSQQAYVLFYJ-RSHDNKΝGGELTHPTHSPGQSSPRPNISQRVNTΝKQAAPGFIGPQLPS HMIKΝPPHLΝGTGPLKDTPSSSMSSPΝGΝSSNΝRASPNΝASASNQΝWSVΝRSSNIPEH PKKQKITIS-HΝKLPNRQCQSQPΝLHSΝSLEΝPTKPNPSSTITΝSANQSTSΝASTMSNSS KNTKPIPRSESCSQPNMΝGKSKLΝSSNLNPYGAESSEDSDEESKGLGKEΝGIGT1NSSH SPGQDAEDEEATPHELQEPMTLΝGAΝSADSDSDPKEΝGLAPDGASCQGQPALHSEΝP FAKAΝGLPGKLMPAPLLSLPEDKΓLETFRLSΝKLKGSTDEMSAPGAERGPPEDRDAEP QPGSPA-AESLEEPDAAAGLSSTKKAPPPRDPGTPATKEGAWEAMAVAPEEPPPSAGE DINGDTAPPDLCDPGSLTGDASPLSQDAKGMIAEGPRDSALAEAPEGLSPAPPARSEEP CEQPLLVOTSGDHARDAQDPSQSLGAPEAAERPPAPNLDMAPAGHPEGDAEPSPGER NEDAAAPK-APGPSPAKEKIGSLL^NDRGHYRSRRERSSSGEPARESRSKTEGHRJTRRR RTCPRERDRQDRHAPEHHPGHGDRLSPGERRSLGRCSHHHSRHRSGNELDWVRHHY TEGERGWGREKFYPDRPRWDRCRYYHDRYALYA-ARDWKPFHGGREHERAGLHERP HKDHNRGRRGCEPARERERHRPSSPRAGAPHALAPHPDRFSHDRTALNAGDNCNLSD l^HEHENGKSRKRRHDSVENSDSHNEKKARRSEOKDPLEEPKAKKHKKSKKKKKSK DKJTRDRDSRHOODSDLSAACSDADLHRH-DgK-KKKKKi SRKSEDFVK^ TSLETNAQFRRAQGGFPLSGGPPLEGNGPFREKTKHLRMESRDDRCRLFEYGQGD

Table 12. Putative promoter sequence of hDUB7 (2 Kb sequence upstream of initiation AUG)

GTAAAGTCTAAACTGAGAAGTGGAAGTGTGAACTGGCTGGAGGTGGAAGGTTGG AAAAGAGTCGGAGAAAAGAACAGCATGTGCAGAGCCCAGAGACAGCAGGGACA AAAGAAAAAAAAACAAGACTTCAGCATGGTGGGAACGTGACGGAGAGGGTGTTT GGCGAGGTTATTAGGTCAGACAATGTGAAGTCCAGACATTAAGATGTTGTGCTGT GGGCAGTTGGGCCACTCCTGAAAGGTGTTCTTTCTTCCTTTCCTTTTCTTTCTTTCT TTTCTTGAGGCAGAGTCTCTCTATGTCAGTCTGGAGTGCAGTGGCATGATCTCGGC TCACTGCAATCTCTGCCTTCCAGGTTCAAGCAATTTTCCTTGCCTCAGCCTCCCAA GTAGCTGGGAATACAGGCGTGCGCCACCATGCCTGGTTAATTTTTTTATTTTTAGT AGAGATGGGGTTTCCCCATGTTGGCCAGGCTGGTCTCGAACTCCTGGACTCAAGT GATCCACCCACTTTGGCCTCCCAAAGTGCTGGGATTACAGGGGTGTGAGCCACTG CGCCCCGCCCGGCCTTTTTTTTTTTTTTTTTTGAGACTTAATCTTGCTCTGTCACCA AGGCTGGATATCAGTGGCACGGTTTTGGCTCTCTGCAACTTCTGTCTCCCAGGTTC AAGCGATTTTCCTGACTCAGCCTCCCAAGTAGTTGAGATTACAGGTACGTGCCAC CACGCCCGGCTAATTTTTGTATTTTTAGTAGAGATGAGGTTTCACTATGTTGGCCA GACTGGTCTCAAACGCCTGACCTCAGGTGATTCACCTGCCTCGGCCTCCCAAAAT GCTGGGATTACAGGTGTGCACCACCATGCCTGGGTAATTTTTGTTTTTCGTAGAGA CAGGGTCTCACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGCGATCT GCCCACCTTGGCCTCCCAAGGTGCTGCAATTATAGGCATGAGCCACCGCGCCCGG CCTCCTGAAAGGTTTTCTACATAGGAGTGGCATGTCTAGATGTGGCTACTGTTGGG CGATTTTAGAAATATCCCTAAAAGCCTTCTGTTGACAGGGTGGCATAACCAGAAG GAAGCCTGGCTGGGAACGCTGGACCTGGCTCTCAGTCCCAGTTGCTGACTGGTTG CTTCATTTTATAGGCCCTGGGGATTCTGTCTGATCTCTCATACGTTCTTTATAAAA ATTAAGTTAATGTATGTCCAGCAGTTGATGCAATGCCCAGTACATAGAAAATGCT CAATTAGTGGTAGCCCTAATATTTTAAAATAGGACTCAGAAAGAAAATTATAATC AAGTCCTTTCATAACAGATATTTGTGTTTGAGTTTGATATCAGTAATGGCTTACGG GTTTTATTTAAAAAGTCATACATTCCATATAAATGAGCCTCTTCAGAAAAATGGTT TTAAAGGTGAGATCTCTATAATTATAATTTTAAAAAATATAATGTATTTCACTTGG TGCCATTTGCACTTTAAGCACAAAATTAAGTCTAGATTTTTTCTGTGTAGTTGATG CTTTTCTCTGAGGAATTATACTCAAATTGAAGATGTAGTCAAATGTATTACTGTGT ATAATTTTTCTAGTTTTAAGCAGTATAGAAGGAAAATATAGGTACTTAGTAAATA AACAGAACTGAGAATTGAAATGTCCAATTATAAACTGAAATGCCAGACTTTTAGG GGGCATGAAATGAAAATGAGAAGTTCTTTTAATCAAATACTTCACTGAAGATTTT AAAATAAAGATTGTTGACATTCAGATTATCATGATGCTAAATGTCCCAAGGGGAT TATTACAGAAATGTTAGAAAGTACTATTGTTTTTATATTTGAGTGATGTGTTTGAA AATCACTTTAAAATGGCTGGAATGATCTTCCAAGATCTAACGGTAGGGTAAGGAG ATTGCTTTTCTCACCTGATGAAACAAATACATACTTTTCATCTTTTGCAGAGTTGA ACAATG

Table 13. Nucleotide sequence of coding region of murine DUB7 (mDUB7)

ATGACCATAGTTGACAAAACTGAACCTTCAGACCCATCAACCTGTCAGAACCAGC CTGGCAGTTGTGAGGCGGTCTCACCTGAAGACATGGACACAGGCTCTGCCAGCTG GGGCGCTGTGTCTTCAATAAGTGATGTCTCAAGTCACACACTTCCATTAGGGCCA GTGCCTGGTGCTGTAGTTTATTCTAACTCGTCTGTACCTGAAAAATCAAAGCCATC ACCACCAAAGGATCAAGTCCTAGGTGATGGCATTGCTCCTCCTCAAAAGGTCCTG TTTCCATCTGAAAAGATTTGTCTTAAGTGGCAACAAAGTCATCGAGTTGGCGCTG GGCTCCAGAATTTGGGCAACACCTGTTTTGCCAATGCCGCATTGCAGTGTCTGACT TACACGCCACCCCTCGCCAATTACATGTTATCCCATGAACACTCCAAGACATGCC ACGCAGAAGGATTTTGTATGATGTGCACGATGCAGACACACATTACCCAGGCACT TAGCAACCCTGGGGATGTTATCAAGCCGATGTTCGTCATCAATGAAATGCGGCGT ATAGCTAGACACTTCCGTTTTGGAAACCAAGAAGATGCCCATGAATTTCTTCAGT ACACGGTCGATGCCATGCAGAAAGCATGTTTAAATGGCAGCAATAAATTAGACA GACACACCCAGGCCACCACCCTGGTCTGCCAGATATTTGGAGGCTACCTAAGATC CCGAGTTAAATGTTTAAATTGCAAGGGTGTTTCAGATACCTTTGATCCATATCTGG ACATAACGTTGGAGATTAAGGCTGCACAGAGTGTTACCAAGGCGTTAGAGCAGTT TGTGAAGCCAGAACAACTGGATGGAGAAAACTCCTACAAGTGCAGCAAGTGCAA AAAAATGGTTCC AGCTTC AAAGAGATTCACAATCC ATAGGTCCTCTAATGTTCTTA CCATCTCACTGAAGCGCTTTGCCAACTTCACCGGTGGAAAGATTGCTAAGGATGT GAAATATCCTGAGTACCTTGATATCCGGCCCTATATGTCTCAGCCCAATGGAGAG CCAATTATTTATGTTTTGTATGCTGTGCTGGTGCACACTGGTTTTAATTGTCATGCT GGCCACTACTTTTGCTACATCAAGGCTAGCAATGGCCTCTGGTATCAGATGAATG ACTCCATCGTGTCCACCAGTGATATCAGAGCAGTGCTTAACCAGCAAGCTTACGT GCTCTTTTATATCAGGTCCCATGATGTGAAAAATGGAGGGGAGTCTGCTCATCCT GCCCATAGCCCCGGCCAATCCTCTCCCCGCCCAGGAGTCAGTCAGCGGGTAGTCA ACAACAAGCAGGTGGCTCCAGGGTTTATTGGACCCCAGCTGCCTTCCCATGTGAT GAAGAACACGCCACACTTGAATGGCACCACGCCAGTGAAAGACACACCAAGTAG TTCTGTGTCAAGCCCTAACGGAAACACCAGCGTCAATAGGGCCAGTCCTGCTACT GCTTCGACTTCTGTGCAGAACTGGTCTGTTACCAGACCCTCAGTTATTCCAGATCA CCCCAAGAAACAAAAAATCACCATCAGTATTCACAACAAGTTGCCTGCTCGCCAG GGTCAGGCACCACTGAATAACAGCCTCCATGGCCCTTGTCTGGAGGCTCCTAGTA AGGCGGCACCCTCCTCCACCATCACTAACCCTTCTGCAATACAGTCTACCTCGAAC GTACCCACAACGTCGACTTCCCCCAGTGAGGCCTGTCCCAAGCCCATGGTGAACG GCAAGGCTAAAGTGGGCGCCAGTGTGCTTGTCCCCTATGGGGCCGAGTCCTCAGA AGAGTCTGATGAGGAGTCGAAGGGCCTGGCCAAGGAGAACGGTGTGGACATGAT GGCCGGCACTCACTCCGATAGGCCAGAAGCTGCTGCAGATGACGGTGCTGAGGCT TCCTCCCATGAGCTTCAAGAACCCGTCCTGCTAAATGGTGCTAATAGCGCAGACA GTGACTCACAAGAGAACAGCCTGGCATTTGACAGTGCCAGCTGCCAGGTCCAGCC CGAGCTACACACAGAAAACCTCTTTTCCAAACTTAATGGTCTTCCTGGAAAGGTG ACGCCTGCTCCTTTGCAGTCTGTTCCTGAAGACAGAATCCTTGAGACCTTCAAGCT TACCAACCAGGCAAAGGGTCCAGCGGGTGAAGAGAGTTGGACTACGACAGGGGG AAGCTCTCCAAAGGACCCTGTTTCACAGCTGGAGCCCATCAGTGATGAGCCCAGT CCCCTTGAGATACCGGAGGCTGTCACCAATGGGAGCACACAGACCCCTTCCACCA CATCACCCCTGGAGCCCACCATCAGCTGTACCAAAGAAGACTCGTCCGTTGTTGT CTCAGCTGAACCTGTGGAGGGTTTGCCTTCCGTCCCTGCTCTTTGTAACAGCACTG GTACTATCTTGGGGGATACCCCAGTGCCCGAATTGTGTGACCCTGGAGACTTGAC TGCCAACCCGAGCCAGCCAACCGAAGCAGTGAAAGGTGATACAGCTGAGAAGGC TCAGGACTCTGCCATGGCTGAAGTGGTGGAGAGGCTGAGCCCTGCTCCCTCAGTA CTCACAGGTGACGGGTGTGAGCAGAAACTCTTACTTTACCTCAGCGCAGAGGGGT CAGAGGAGACAGAAGACTCTTCCAGAAGCTCGGCGGTCTCTGCTGACACGATGCC CCCTAAGCCTGACAGGACCACCACCAGCTCCTGTGAAGGGGCTGCCGAGCAGGCT GCTGGGGACAGAGGCGATGGAGGCCATGTGGGACCCAAAGCTCAGGAGCCTTCC CCAGCCAAGGAAAAGATGAGCAGCCTCCGGAAAGTGGACCGAGGACACTATCGG AGCCGGAGAGAGCGCTCCTCCAGTGGGGAGCACGTGAGGGACAGCAGGCCCCGG CCGGAGGACCATCACCATAAGAAGCGGCACTGCTACAGCCGAGAGCGGCCCAAG CAGGACCGACACCCTACTAATTCATACTGCAATGGGGGCCAGCACTTGGGCCACG GGGACAGAGCCAGCCCTGAGCGCCGCTCCCTGAGCAGGTATAGTCACCACCACTC ACGGATTAGGAGTGGCCTGGAGCAGGACTGGAGCCGGTACCACCATTTGGAAAA TGAGCATGCTTGGGTCAGGGAGAGATTCTACCAGGACAAGCTGCGGTGGGACAA GTGCAGGTATTACCACGACAGGTACACGCCCCTATACACGGCCCGGGACGCCCGA GAATGGCGGCCTCTGCATGGTCGTGAGCATGACCGCCTTGTCCAGTCTGGACGGC CATACAAGGACAGCTACTGGGGCCGCAAGGGCTGGGAGCTGCAATCCCGGGGGA AGGAACGGCCCCACTTCAACAGCCCCCGAGAGGCCCCTAGCCTTGCTGTGCCCCT CGAGAGACATCTCCAAGAGAAGGCTGCGCTGAGTGTGCAGGACAGCAGCCACAG TCTCCCTGAGCGCTTTCATGAACACAAAAGTGTCAAGTCGAGGAAGCGGAGGTAT GAGACTCTAGAAAATAATGATGGCCGTCTAGAAAAGAAAGTCCACAAAAGCCTG GAGAAGGACACGCTAGAGGAGCCAAGGGTGAAGAAGCACAAAAAGTCTAAAAA GAAAAAGAAGTCCAAAGATAAACACCGGGATCGAGAAAGCAGGCACCAGCAGG AGTCTGATTTTTCAGGAGCATACTCTGATGCTGACCTCCATAGACACCGGAAGAA AAAGAAGAAAAAGAAAAGGCATTCCAGGAAGTCGGAGGACTTTATAAAGGATGT TGAGATGCGTTTACCGAAGCTCTCCAGCTACGAGGCCGGCGGCCATTTCCGGAGA ACAGAGGGCAGCTTTCTCCTGGCTGATGGTCTGCCTGTGGAAGACAGCGGCCCTT TCCGGGAGAAAACGAAGCATTTAAGGATGGAAAGCCGGCCTGACAGATGCCGTC TGTCGGAGTATGGCCAGGATTCAACATTTTGA

Table 14. Deduced amino acid sequence of coding region of mDUB 7 C-terminal potential nuclear localization (as well as targeting) sequences are underlined.

MTIVDKTEPSDPSTCQNQPGSCEANSPEDMDTGSASWGANSSISDNSSHTLPLGPNPG ANNYSΝSSNPEKSKPSPPKDQNLGDGIAPPQKNLFPSEKICLKWQQSHRNGAGLQΝL GΝTCFAΝAALQCLTYTPPLAΝYMLSHEHSKTCHAEGFCMMCTMQTHITQALSΝPGD NΠ PMFNLΝEMRRIARHFRFGΝQEDAHEFLQYTNDAMQKACLΝGSΝKLDRHTQATT LNCQIFGGYLRSRVKCLΝCKGNSDTFDPYLDITLEIKAAQSNTKALEQFVKPEQLDGE ΝSYKCSKCKKM ASKRFTIIMSSΝNLTISLKΕFAΝFTGGKJ^KDNKYPEYLDIRPY^ SQPΝGEPΠYVLYANLNHTGFΝCHAGHYFCYD ASΝGLWYQMΝDSINSTSDIRANLΝQ QAYNLFYJRSHDVKΝGGESAHPAHSPGQSSPRPGVSQRNNΝΝKQNAPGFIGPQLPSH NMKΝTPHLΝGTTPVKDTPSSSNSSPΝGΝTSNΝRASPATASTSNQΝWSVTRPSNIPDHP KKQKITIS1ILΝKLPARQGQAPLΝΝSLHGPCLEAJSE-AAPSSTITΝPSAIQSTSΝVPTTSTS PSEACPKPMVΝGKAKNGASVLNPYGAESSEESDEESKGLAKEΝGNDMMAGTHSDRP EAAADDGAEASSHELQEPNLLΝGAΝSADSDSQEΝSLAFDSASCQNQPELHTEΝLFSK LΝGLPGKNTPAPLQSNPEDRLLETFKLTΝQAKGPAGEESWTTTGGSSPKDPNSQLEPIS DEPSPLEIPEANTΝGSTQTPSTTSPLEPTISCTKEDSSNNNSAEPNEGLPSVPALCΝSTGT ILGDTPNPELCDPGDLTAΝPSQPTEAVKGDTAEKAQDSAMAENNERLSPAPSNLTGD GCEQKLLLYLSAEGSEETEDSSRSSANSADTMPPKPDRTTTSSCEGAAEQAAGDRGD GGHVGPKAQEPSPAKEKMSSLI^NDRGHYTISRRERSSSGEHNRDSRPRPEDHHHKK RHCYSRERPKQDRHPTΝSYCΝGGQHLGHGDRASPERRSLSRYSHHHSRIRSGLEQDW SRYΉHLEΝEHAWVRERFYQDKLRWDKCRYYHDRYTPLYTARDAREWRPLHGREHD RLNQSGRPYIΠDSYWGRKGWELQSRGKERPHFΝSPREAPSLANPLERHLQEKAALSN QDSSHSLPEP^HEHKSNKSRKRRYETLEΝI OGRLEKKVILKSLEKDTLEEPRNKKHKK SKKKKKSKDKHRDRESRHOOESDFSGAYSDADLF- HRKKKKKKKRHSRKSEDFIK^

NEMRLPKLSSYEAGGHFRRTEGSFLLADGLPNEDSGPFREKTKHLRMESRPDRCRLSE

YGQDSTF

Table 15. Nucleotide sequence alignment of hDUB7 and mDUB7

HDUB7 ATGACCATAGTTGACAAAGCTTCTGAATCTTCAGACCCATCAGCCTATCAGAATCAGCCT 60 MDUB7 ATGACCATAGTTGACAAAA---CTGAACCTTCAGACCCATCAACCTGTCAGAACCAGCCT 57 ****************** ***** ************** *** ****** ******

HDUB7 GGCAGCTCCGAGGCAGTCTCACCTGGAGACATGGATGCAGGTTCTGCCAGCTGGGGTGCT 120 MDUB7 GGCAGTTGTGAGGCGGTCTCACCTGAAGACATGGACACAGGCTCTGCCAGCTGGGGCGCT 117

***** * ***** ********** ********* **** ************** ***

HDUB7 GTGTCTTCATTGAATGATGTGTCAAATCACACACTTTCTTTAGGACCAGTACCTGGTGCT 180 MDUB7 GTGTCTTCAATAAGTGATGTCTCAAGTCACACACTTCCATTAGGGCCAGTGCCTGGTGCT 177

********* * * ****** **** ********** * ***** ***** *********

HDUB7 GTAGTTTATTCGAGTTCATCTGTACCTGATAAATCAAAACCATCACCACAAAAGGATCAA 240 MDUB7 GTAGTTTATTCTAACTCGTCTGTACCTGAAAAATCAAAGCCATCACCACCAAAGGATCAA 237 *********** * ** *********** ******** ********** **********

HDUB7 GCCCTAGGTGATGGCATCGCTCCTCCACAGAAAGTTCTTTTCCCATCTGAGAAGATTTGT 300 MDUB7 GTCCTAGGTGATGGCATTGCTCCTCCTCAAAAGGTCCTGTTTCCATCTGAAAAGATTTGT 297

* *************** ******** ** ** ** ** ** ******** *********

HDUB7 CTTAAGTGGCAACAAACTCATAGAGTTGGAGCTGGGCTCCAGAATTTGGGCAATACCTGT 360 MDUB7 CTTAAGTGGCAACAAAGTCATCGAGTTGGCGCTGGGCTCCAGAATTTGGGCAACACCTGT 357

**************** **** ******* *********************** ******

HDUB7 TTTGCCAATGCAGCACTGCAGTGTTTAACCTACACACCACCTCTTGCCAATTACATGCTA 420 MDUB7 TTTGCCAATGCCGCATTGCAGTGTCTGACTTACACGCCACCCCTCGCCAATTACATGTTA 17 *********** *** ******** * ** ***** ***** ** ************ **

HDUB7 TCACATGAACACTCCAAAACATGTCATGCAGAAGGCTTTTGTATGATGTGTACAATGCAA 480 MDUB7 TCCCATGAACACTCCAAGACATGCCACGCAGAAGGATTTTGTATGATGTGCACGATGCAG 477

** ************** ***** ** ******** ************** ** ***** HDUB7 GCACATATTACCCAGGCACTCAGTAATCCTGGGGACGTTATTAAACCAATGTTTGTCATC 540 MDUB7 ACACACATTACCCAGGCACTTAGCAACCCTGGGGATGTTATCAAGCCGATGTTCGTCATC 537 **** ************** ** ** ******** ***** ** ** ***** ******

HDUB7 AATGAGATGCGGCGTATAGCTAGGCACTTCCGTTTTGGAAACCAAGAAGATGCCCATGAA 600 MDUB7 AATGAAATGCGGCGTATAGCTAGACACTTCCGTTTTGGAAACCAAGAAGATGCCCATGAA 597 ***** ***************** ************************************

HDUB7 TTCCTTCAATACACTGTTGATGCTATGCAGAAAGCATGCTTGAATGGCAGCAATAAATTA 660 MDUB7 TTTCTTCAGTACACGGTCGATGCCATGCAGAAAGCATGTTTAAATGGCAGCAATAAATTA 657 ** ***** ***** ** ***** ************** ** ******************

HDUB7 GACAGACACACCCAGGCCACCACTCTTGTTTGTCAGATATTTGGAGGATACCTAAGATCT 720 MDUB7 GACAGACACACCCAGGCCACCACCCTGGTCTGCCAGATATTTGGAGGCTACCTAAGATCC 717 *********************** ** ** ** ************** ***********

HDUB7 AGAGTCAAATGTTTAAATTGCAAGGGCGTTTCAGATACTTTTGATCCATATCTTGATATA 780 MDUB7 CGAGTTAAATGTTTAAATTGCAAGGGTGTTTCAGATACCTTTGATCCATATCTGGACATA 777 **** ******************** *********** ************** ** *** HDUB7 ACATTGGAGATAAAGGCTGCTCAGAGTGTCAAC-AGGCATTGGAGCAGTTTGTGAAGCCG 840

MDUB7 ACGTTGGAGATTAAGGCTGCACAGAGTGTTACCAAGGCGTTAGAGCAGTTTGTGAAGCCA 837 ** ******** ******** ******** * ****** ** *****************

HDUB7 GAACAGCTTGATGGAGAAAACTCGTACAAGTGCAGCAAGTGTAAAAAGATGGTTCCAGCT 900

MDUB7 GAACAACTGGATGGAGAAAACTCCTACAAGTGCAGCAAGTGCAAAAAAATGGTTCCAGCT 897 ***** ** ************** ***************** ***** ************

HDUB7 TCAAAGAGGTTCACTATCCATAGATCCTCTAATGTTCTTACACTTTCTCTGAAACGTTTT 960

MDUB7 TCAAAGAGATTCACAATCCATAGGTCCTCTAATGTTCTTACCATCTCACTGAAGCGCTTT 957

******** ***** ******** ***************** * ** ***** ** ***

HDUB7 GCAAATTTTACCGGTGGAAAAATTGCTAAGGATGTGAAATACCCTGAGTATCTTGATATT 1020 MDUB7 GCCAACTTCACCGGTGGAAAGATTGCTAAGGATGTGAAATATCCTGAGTACCTTGATATC 1017

** ** ** *********** ******************** ******** ********

HDUB7 CGGCCATATATGTCTCAACCCAACGGAGAGCCAATTGTCTACGTCTTGTATGCAGTGCTG 1080 MDUB7 CGGCCCTATATGTCTCAGCCCAATGGAGAGCCAATTATTTATGTTTTGTATGCTGTGCTG 1077

***** *********** ***** ************ * ** ** ******** ******

HDUB7 GTCCACACTGGTTTTAATTGCCATGCTGGCCATTACTTCTGCTACATAAAAGCTAGCAAT 1140 MDUB7 GTGCACACTGGTTTTAATTGTCATGCTGGCCACTACTTTTGCTACATCAAGGCTAGCAAT 1137

** ***************** *********** ***** ******** ** ********* HDUB7 GGCCTCTGGTATCAAATGAATGACTCCATTGTATCTACCAGTGATATTAGATCGGTACTC 1200

MDUB7 GGCCTCTGGTATCAGATGAATGACTCCATCGTGTCCACCAGTGATATCAGAGCAGTGCTT 1197

************** ************** ** ** *********** *** * ** **

HDUB7 AGCCAACAAGCCTATGTGCTCTTTTATATCAGGTCCCATGATGTGAAAAATGGAGGTGAA 1260 MDUB7 AACCAGCAAGCTTACGTGCTCTTTTATATCAGGTCCCATGATGTGAAAAATGGAGGGGAG 1257

* *** ***** ** ***************************************** **

HDUB7 CTTACTCATCCCACCCATAGCCCCGGCCAGTCCTCTCCCCGCCCCGTCATCAGTCAGCGG 1320 MDUB7 TCTGCTCATCCTGCCCATAGCCCCGGCCAATCCTCTCCCCGCCCAGGAGTCAGTCAGCGG 1317 * ******* **************** ************** * ***********

HDUB7 GTTGTCACCAACAAACAGGCTGCGCCAGGCTTTATCGGACCACAGCTTCCCTCTCACATG 1380 MDUB7 GTAGTCAACAACAAGCAGGTGGCTCCAGGGTTTATTGGACCCCAGCTGCCTTCCCATGTG 1377

** **** ****** **** ** ***** ***** ***** ***** ** ** ** **

HDUB7 ATAAAGAATCCACCTCACTTAAATGGGACTGGACCATTGAAAGACACGCCAAGCAGTTCC 1440 MDUB7 ATGAAGAACACGCCACACTTGAATGGCACCACGCCAGTGAAAGACACACCAAGTAGTTCT 1437

** ***** ** ***** ***** ** *** ********** ***** ***** HDUB7 ATGTCGAGTCCTAACGGGAATTCCAGTGTCAACAGGGCTAGTCCTGTTAATGCTTCAGCT 1500 MDUB7 GTGTCAAGCCCTAACGGAAACACCAGCGTCAATAGGGCCAGTCCTGCTACTGCTTCGACT 1497 **** ** ******** ** **** ***** ***** ******* ** ****** **

HDUB7 TCTGTCCAAAACTGGTCAGTTAATAGGTCCTCAGTGATCCCAGAACATCCTAAGAAACAA 1560 MDUB7 TCTGTGCAGAACTGGTCTGTTACCAGACCCTCAGTTATTCCAGATCACCCCAAGAAACAA 1557 ***** ** ******** **** ** ******* ** ***** ** ** *********

HDUB7 AAAATTACAATCAGTATTCACAACAAGTTGCCTGTTCGCCAGTGTCAGTCTCAACCTAA- 1619

MDUB7 AAAATCACCATCAGTATTCACAACAAGTTGCCTGCTCGCCAGGGTCAGGCACCACTGAAT 1617 ***** ** ************************* ******* ***** * * ** **

HDUB7 CCTTCATAGTAATTCTTTGGAGAACCCTACCAAGCCCGTTCCCTCTTCTACCATT 1674

MDUB7 AACAGCCTCCATGGCCCTTGTCTGGAGGCTCCTAGTAAGGCGGCACCCTCCTCCACCATC 1677 *** *** * ** * ***** **** *** * * ***** ** ***** HDUB7 ACCAA TTCTGCAGTACAGTCTACCTCGAACGCATCTACGATGTCAGTTTCTAGTAAA 1731

MDUB7 ACTAACCCTTCTGCAATACAGTCTACCTCGAACGTACCCACAACGTCGACTTC 1730

** ** ******* ****************** * * ** * *** ***

HDUB7 GTAACAAAACCGATCCCCCGCAGTGAATCCTGCTCCCAGCCCGTGATGAATGGCAAATCC 1791

MDUB7 CCCCAGTGAGGCCTGTCCCAAGCCCATGGTGAACGGCAAGGCT 1773

** ****** **** ** ***** ** **** ***** *

HDUB7 AAGCTGAACTCCAGCGTGCTGGTGCCCTATGGCGCCGAGTCCTCTGAGGACTCTGACGAG 1851

MDUB7 AAAGTGGGCGCCAGTGTGCTTGTCCCCTATGGGGCCGAGTCCTCAGAAGAGTCTGATGAG 1833 ** ** * **** ***** ** ******** *********** ** ** ***** ***

HDUB7 GAGTCAAAGGGGCTGGGCAAGGAGAATGGGATTGGTACGATTGTGAGCTCCCACTCTCCC 1911 MDUB7 GAGTCGAAGGGCCTGGCCAAGGAGAACGGTGTGGACATGATGGCCGGCACTCACTCCGAT 1893

***** ***** **** ********* ** * * * *** * ** * *****

HDUB7 GGCCAAGA TGCCGAAGATGAGG AGGCCACTCCGCACGAGCTTCAAGAACCC 1962 MDUB7 AGGCCAGAAGCTGCTGCAGATGACGGTGCTGAGGCTTCCTCCCATGAGCTTCAAGAACCC 1953

****** * ** ***************

HDUB7 ATGACCCTAAACGGTGCTAATAGTGCAGACAGCGACAGTGACCCGAAAGAAAACGGCCTA 2022 MDUB7 GTCCTGCTAAATGGTGCTAATAGCGCAGA CAGTGACTCACAAGAGAACAGCCTG 2007

***** *********** ***** ******* * **** *** ****

HDUB7 GCGCCTGATGGTGCCAGCTGCCAAGGCCAGCCTGCCCTGCACTCAGAAAATCCCTTTGCT 2082

MDUB7 GCATTTGACAGTGCCAGCTGCCAGGTCCAGCCCGAGCTACACACAGAAAACCTCTTTTCC 2067 ** *** ************* * ****** * ** *** ******* * **** *

HDUB7 AAGGCAAACGGTCTTCCTGGAAAGTTGATGCCTGCTCCTTTGCTGTCTCTCCCAGAAGAC 2142

MDUB7 AAACTTAATGGTCTTCCTGGAAAGGTGACGCCTGCTCCTTTGCAGTCTGTTCCTGAAGAC 2127 ** ** *************** *** ************** **** * ** ******

HDUB7 7ΛAAATCTTAGAGACCTTCAGGCTTAGCAACAAACTGAAAGGCTCGACGGATGAAATGAGT 2202 MDUB7 AGAATCCTTGAGACCTTCAAGCTTACCAACCAGGCAAAGGGTCCAGCGGGTGAAGAGAGT 2187

********** ***** **** *** ****

HDUB7 GCACCTGGAGCAGAGAGGGGCCCTCCCGAGGACCGCGACGCCGAGCCTCAGCCTGGCAGC 2262 MDUB7 TGGACTACGACAGGGGGAAGCTCTCCAAAGGACCCTGΪTTCACAGCTGGAGCCCATCAGT 2247

** *** * * ** **** ****** * * *** **** ***

HDUB7 CCCGCCGCCGAATCCCTGGAGGAGCCAGATGCGGCCGCCGGCCTCAGCA GCACCAAG 2319 MDUB7 GATGAGCCCAGTCCCCTTGAGATACCGGAGGCTGTCACCAATGGGAGCACACAGACCCCT 2307

* ** **** *** ** ** ** * * ** **** *** HDUB7 AAGGCTCCGCCGCCCCGCGATCCCGGCACCCCCGCTACCAAAGAAGGCGCCTGGGAGGCC 2379 MDUB7 TCCACCACATCACCCCTGGAGCCCACCATCAGCTGTACCAAAGAAGACTCGTCCGTTGTT 2367

* * * **** ** *** ** * * *********** * * * * *

HDUB7 ATGGCCGTCGCCCCCGAGGAG CCTCCGCCC AGCGCCGGCGAG 2421

MDUB7 GTCTCAGCTGAACCTGTGGAGGGTTTGCCTTCCGTCCCTGCTCTTTGTAACAGCACTGGT 2427

** * **** **** **

HDUB7 GACATCGTGGGGGACACAGCACCCCCTGACCTGTGTGATCCCGGGAGCTTAACAGGCGAT 2481 MDUB7 ACTATCTTGGGGGATACCCCAGTGCCCGAATTGTGTGACCCTGGAGACTTGACTGCCAAC 2487 *** ******* ** ** ** ** ******* ** ** *** ** * * *

HDUB7 GCGAGCCCGTTGTCCCAGGACGCAAAGGGGATGATCGCGGAGGGCCCGCGGGACTCGGCG 25 1 MDUB7 CCGAGCCAGCCAACCGAAGCAGTGAAAGGTGATACAGCTGAGAAGGCTCAGGACTCTGCC 2547

****** * ** *** * * ****** ** HDUB7 TTGGCGGAAGCCCCGGAAGGGTTGAGTCCGGCTCCGCCTGCGCGGTCGGAGGAGCCCTGC 2601 MDUB7 ATGGCTGAAGTGGTGGAGAGGCTGAGCCCTGCTCCCTCAGTACTCACAGGTGACGGGTGT 2607

**** **** ** **** ** *****

HDUB7 GAGCAGCCACTCCTTGTTCACCCCAGCGGGGACCACGCCCGGGACGCTCAGGACCCATCC 2661 MDUB7 GAGCAGAAACTCTTACTTTACCTCAGCGCAGAGGGGTCAGAGGAGACAGAAGACTCTTCC 2667

****** **** * ** *** ***** *** * ***

HDUB7 CAGAGCTTGGGCGCACCCGAGGCCGCAGAGCGGCCGCCAGCTCCTGTGCTGGACATGGCC 2721 MDUB7 AGAAGCTCGGCGGTCTCTGCTGACACGATGC CCCCTAAGCCTGACAGGACC 2718

**** ** **** * **

HDUB7 CCGGCCGGTCACCCGGAAGGGGACGCTGAGCCTAGCCCCGGCGAGAGGGTCGA-GGACGC 2780 MDUB7 ACCACCAGCTCCTGTGAAGGGGCTGCCGAGCAGGCTGCTGGGGACAGAGGCGATGGAGGC 2778

******* ** **** * ** ** ** * *** *** **

HDUB7 C--GCGGCGCCGAAAGCCCCAGGCCCTTCCCCAGCGAAGGAGAAAATCGGCAGCCTCAGA 2838 MDUB7 CATGTGGGACCCAAAGCTCAGGAGCCTTCCCCAGCCAAGGAAAAGATGAGCAGCCTCCGG 2838 * * ** ** ***** * * *********** ***** ** ** ******** *

HDUB7 AAGGTGGACCGAGGCCACTACCGCAGCCGGAGAGAGCGCTCGTCCAGCGGGGAGCCCGCC 2898 MDUB7 AAAGTGGACCGAGGACACTATCGGAGCCGGAGAGAGCGCTCCTCCAGTGGGGAGCACGTG 2898

** *********** ***** ** ***************** ***** ******* **

HDUB7 AGAGAGAGCAGGAGCAAGACTGAGGGCCACCGTCACCGGCGGCGCCGCACCTGCCCCCGG 2958 MDUB7 AGGGACAGCAGGCCCCGGCCGGAGGACCATCACCATAAGAAGCGGCACTGCTACAGCCGA 2958

** ** ****** * * * **** *** * ** * *** * * ** * ***

HDUB7 GAGCGCGACCGCCAGGACCGCCACGCCCC GGAGCACCACCCC 3000

MDUB7 GAGCGGCCCAAGCAGGACCGACACCCTACTAATTCATACTGCAATGGGGGCCAGCACTTG 3018

******** *** ** ***

HDUB7 GGCCACGGCGACAGGCTCAGCCCTGGCGAGCGCCGCTCTCTGGGCAGGTGCAGTCACCAC 3060 MDUB7 GGCCACGGGGACAGAGCCAGCCCT GAGCGCCGCTCCCTGAGCAGGTATAGTCACCAC 3075

******** ***** ******* *********** *** ****** *********

HDUB7 CACTCCCGACACCGGAGCGGGGTGGAGCTGGACTGGGTCAGACACCACTACACCGAGGGC 3120 MDUB7 CACTCACGGATTAGGAGTGGCCTGGAGCAGGACTGGAGCCGGTACCACCATTTGGAAAAT 3135

***** ** **** ** ****** *******

HDUB7 GAGCGTGGCTGGGGCCGGGAGAAGTTCTACCCCGACAGGCCGCGCTGGGACAGGTGCCGG 3180 MDUB7 GAGCATGCTTGGGTCAGGGAGAGATTCTACCAGGACAAGCTGCGGTGGGACAAGTGCAGG 3195

**** ** **** * ****** ******* **** ** *** ******* **** ** HDUB7 TACTACCATGACAGGTACGC CCTGTACGCTGCCCGGGACT GGAAGCCCTTCCA 3233

MDUB7 TATTACCACGACAGGTACACGCCCCTATACACGGCCCGGGACGCCCGAGAATGGCGGCCT 3255 ** ***** ********* * *** *** * ********* *** * **

HDUB7 CGGC--GGCCGCGAGCACGAGCGGGCCGGGCTGCACGAGCGGCCGCACAAGGACCACAAC 3291 MDUB7 CTGCATGGTCGTGAGCATGACCGCCTTGTCCAGTCTGGACGGCCATACAAGGACAGCTAC 3315 * ** ** ** ***** ** ** * * * * ***** ******** * **

HDUB7 CGGGGCCGTAGGGGCTGCGAGCCGG CCCGGGAGAGGGAGCGGCACCGCCCCAGCAGC 3348

MDUB7 TGGGGCCGCAAGGGCTGGGAGCTGCAATCCCGGGGGAAGGAACGGCCCCACTTCAACAGC 3375 ******* * ****** **** * ****** ** *** **** ** * ** ****

HDUB 7 CCCCGCGCAGGCGCGCCCCACGCCCTCGCCCCGCACCCCGACCGCTTCTCCCACGACAGA 3408

MDUB 7 CCCCGAGAGG CCCCTAGCCTTGCTGTGCCCCTCGAGAGACATCTCCAAGAGAAG 3429

***** * * *** *** ** ** ** *** * *** ** * HDUB7 ACTGCACT TGTAGCCGGAGACAACTGTAACCTCTCTGATCGGTTTCACGAACACGAA 3465

MDUB7 GCTGCGCTGAGTGTGCAGGACAGCAGCCACAGTCTCCCTGAGCGCTTTCATGAACACAAA 3489

**** ** *** **** ** ***** ****** ** HDUB7 AATGGAAAGTCCCGGAAACGGAGACACGACAGTGTGGAGAACAGTGACAGTCATGTTGAA 3525 MDUB7 AGTGTCAAGTCGAGGAAGCGGAGGTATGAGACTCTAGAAAATAATGATGGCCGTCTAGAA 3549

* ** ***** **** ***** * ** * * * ** ** * *** * * * * ***

HDUB7 AAGAAAGCCCGGAGGAGCGAACAGAAGGATCCTCTAGAAGAGCCTAAAGCAAAGAAGCAC 3585 MDUB7 AAGAAAGTCCACAAAAGCCTGGAGAAGGACACGCTAGAGGAGCCAAGGGTGAAGAAGCAC 3609

******* ** * *** ******* * ***** ***** * * *********

HDUB7 AAAAAATCAAAGAAGAAAAAGAAATCCAAAGACAAACACCGAGACCGCGACTCCAGGCAT 3645 MDUB7 AAAAAGTCTAAAAAGAAAAAGAAGTCCAAAGATAAACACCGGGATCGAGAAAGCAGGCAC 3669

***** ** ** *********** ******** ******** ** ** ** ******

HDUB7 CAGCAGGACTCAGACCTCTCAGCAGCGTGCTCTGACGCTGACCTCCACAGACACAAAAAA 3705 MDUB7 CAGCAGGAGTCTGATTTTTCAGGAGCATACTCTGATGCTGACCTCCATAGACACCGGAAG 3729

******** ** ** * **** *** * ****** *********** ****** **

HDUB7 AAGAAGAAGAAAAAGAAGAGACATTCAAGAAAATCAGAGGACTTTGTTAAAGATTCAGAA 3765 MDUB7 AAAAAGAAGAAAAAGAAAAGGCATTCCAGGAAGTCGGAGGACTTTATAAAGGATGTTGAG 3789

** ************** ** ***** ** ** ** ********* * ** *** ** HDUB7 CTGCACTTACCCAGGGTCACCAGCTTGGAGACTGTCGCCCAGTTCCGGAGAGCCCAGGGT 3825

MDUB7 ATGCGTTTACCGAAGCTCTCCAGCTACGAGGCCGGCGGCCATTTCCGGAGAACAGAGGGC 3849

*** ***** * * ** ****** *** * * ** *** ********* * ****

HDUB7 GGCTTTCCTCTCTCTGGTGGCCCGCCTCTGGAAGGCGTCGGACCTTTCCGTGAGAAAACG 3885 MDUB7 AGCTTTCTCCTGGCTGATGGTCTGCCTGTGGAAGACAGCGGCCCTTTCCGGGAGAAAACG 3909 ****** ** *** *** * **** ****** * *** ******** *********

HDUB7 AAACACTTACGGATGGAAAGCAGGGATGACAGGTGTCGTCTCTTTGAGTATGGCCAGGGT 3945 MDUB7 AAGCATTTAAGGATGGAAAGCCGGCCTGACAGATGCCGTCTGTCGGAGTATGGCCAGGAT 3969 ** ** *** *********** ** ****** ** ***** * ************* *

HDUB7 GATTGA 3951

MDUB7 TCAACATTTTGA 3981

Table 16. Deduced amino acid sequence alignment of hDUB7 and mDUB7

HDUB7 MTIVDKASESSDPSAYQNQPGSSEAVSPGDMDAGSAS GAVSSLNDVSNHTLS GPVPGA 60 MDUB7 MTIVDKT-EPSDPSTCQNQPGSCΞAVSPEDMDTGSASWGAVSSISDVSSHTLPLGPVPGA 59 ******. * ****. ****** ***** ***.**********. *** *** *******

HDUB7 WYSSSSVPDKSKPSPQKDQALGDGIAPPQKVLFPSEKICLKWQQTHRVGAGLQN GNTC 120 MDUB7 WYSNSSVPEKSKPSPPKDQVLGDGIAPPQKVLFPSEKICLK QQSHRVGAGLQNLGNTC 119

**** _ **** _; ****** *** _ ************************ ; **************

HDUB7 PANAA QCLTYTPP ANyMLSHΞHSKTCHAEGFCMMCTMQAHITQALSNPGDVIKPMFVI 180 MDUB7 FANAALQCLTYTPPLA-.YMLSHEHS TCHAEGFCMMCTMQTHITQA SNPGDVIKPMFVI 179 ************************************************************ HDUB7 NEMRRIARHFRFGNQEDAHΞFLQYTVDAMQKAC NGSNKLDRHTQATTLVCQIFGGY RS 240 MDUB7 NEMRRIARHFRFGNQEDAHEFLQYTVDAMQKACLNGSNKLDRHTQATTLVCQIFGGY RS 239 ************************************************************

HDUB7 RVKCLNCKGVSDTFDPY DITLEIKAAQSVNKALEQFVKPEQLDGENSYKCSKCKKMVPA 300 MDUB7 RVKCLNCKGVSDTFDPYLDITLEIKAAQSVTKA EQFVKPEQLDGENSYKCS CKKMVPA 299 ****************************** _Φ *****************************

HDUB7 SKRFTIHRSSNVLT SLKRFANFTGGKIAKDVKYPEY DIRPYMSQPNGEPIVYVLYAVL 360 MDUB7 SKKFTIHRSSNVLTISLKRFANFTGGKIAKDVKYPEYLDIRPYMSQPNGEPIIYVLYAVL 359

************** ************************************** ;*******

HDUB7 VHTGFNCHAGHYFCYIKASNGLWYQMNDSIVSTSDIRSVLSQQAYVLFYIRSHDVKNGGE 420 MDUB7 VHTGFNCHAGHYFCYIKASNGLWYQMNDSIVSTSDIRAVLNQQAYVLFYIRSHDVKNGGE 419

************************************* . ** _^ *******************

HDUB7 THPTHSPGQSSPRPVISQRWTNKQAAPGFIGPQLPSHMIKNPPHLNGTGPL DTPSSS 480 MDUB7 SAHPAHSPGQSSPRPGVSQRWNNKQVAPGFIGPQ PSHVMKNTPH NGTTPVKDTPSSS 479

• ** • ********** • ***** _^ *** _^ ************ ..** _^ ****** * .*******

HDUB7 MSSPNGNSSVNRASPVNASASVQNWSVNRSSVIPEHPKKQKITISIH KLPVRQCQSQPN 540 MDUB7 VSSPNGNTSVNRASPATASTSVQN SVTRPSVIPDHPKKQKITISIH K PARQGQAPLN 539

.******.*******_ **.*******_* ****.****************_** * . *

HDUB7 - -LHSNSLENPTKPVPSSTITN-SAVQSTSNASTMSVSSKVTKPIPRSESCSQPVMNGKS 597 MDUB7 NSLHGPCLEAPSKAAPSSTITNPSAIQSTSNVPTTSTS PSEACPKPMVNGKA 591

** ** *•* ******* ******** * * * **.* .*..***.

HDUB7 KLNSSVLVPYGAESSEDSDEESKGLGKEMGIGTIVSSHS- -PGQDAED-EEATPHELQEP 654 MDUB7 KVGASVLVPYGAESSEESDEESKGLAKENGVDMMAGTHSDRPΞAAADDGAΞASSHELQEP 651 *;_ .************;******** ****._ :.. :** * *;* **. ******

HDUB7 MTLNGANSADSDSDPKENGLAPDGASCQGQPA HSENPFAKA1.GLPGKLMPAPLLSLPED 714 MDUB7 V LNGANSADSDS - -QENSLAFDSASCQVQPΞLHTENLFS LNG PGKVTPAP QSVPED 709

. *********** .** ** * **** ** **.** *.* ******. **** *-***

HDUB7 KI ETFRLSNKLKGSTDEMSAPGAERGPPEDRDAEPQPGSPAAΞSLEEPDAAA-GLSSTK 773 MDUB7 RILETFKLTNQAKGPAGEES TTTGGSSPKDPVSQLEPISDEPSPLEIPEAVTNGSTQTP 769 .*****.*.*. ** . * * _t . ..*:* :: : * * ...** *_:*.: * _:.*

HDUB7 KAPPPRDPGTPATKEGA EAMAVAPEEPPP SAGEDIVGDTAPPDLCDPGSLTGD 827 MDUB7 STTSP EPTISCTKEDSSVWSAEPVEGLPSVPALCNSTGTILGDTPVPELCDPGDLTAN 829 .:..* : * ..***.: .::. * * * .: *.***_ι *.***** ** .

HDUB7 ASPLSQDAKGMIAEGPRDSA AEAPEGLSPAPPARSEEPCEQPLLVHPSGDHARDAQDPS 887 MDUB7 PSQPTEAVKGDTAEKAQDSAMAEWERLSPAPSVLTGDGCΞQKLLLYLSAEGSEETEDSS 889 _^ * .. _^ ** ** •***.**_ι * ***** _# . . *** **.. *.; _:._:::*.*

HDUB7 QSLGAPEAAERPPAPVLDMAPAGHPEGDAEPSPGERVED-AAAPKAPGPSPAKEKIGS R 946 MDUB7 RSS-AVSADTMPPKP--DRTTTSSCEGAAEQAAGDRGDGGHVGP AQEPSPAKEKMSSLR 946 . * * _ * ** * * _:._:. ** ** :.*_:* :. .. *** *******;_***

HDUB7 KVDRGHYRSRRERSSSGEPARESRSKTEGHRHRRRRTCPRERDRQDRHAP EHHP 1000 MDUB7 KVDRGHYRSRRERSSSGΞHVRDSRPRPEDHHHKKRHCYSRERPKQDRHPTNSYCNGGQHL 1006 ****************** .*:**._:,*.*:*_::*_{: #} *** _; **** _ _{# ;}*

HDUB7 GHGDRLSPGERRSLGRCSHHHSRHRSGVELD VRHHYTΞGERGWGREKFYPDRPRWDRCR 1060 MDUB7 GHGDRASP-ERRSLSRYSHHHSRIRSGLEQD SRYHHLENΞHA VRΞRFYQDKLR DKCR 1065

***** ** ***** * ****** ***.* ** *_;*_; * *. * **.** *. ***.**

HDUB7 YYHDRYA-LYAAR- - -D KPFHGGREHERAGLHERPHKDHNRGRRGCEP-ARERERHRPS 1115 MDUB7 YYHDRYTPLYTARDARE RPLHG-REHDR VQSGRPYKDSYWGRKGWELQSRGKERPHFN 1124 ******. **.** .*.*.** ***.* **.** **.* * .* .** .

HDUB7 SPRAGAPHALAPHPDRFSHDRTALVAGDNCN-LSDRFHEHΞNGKSRKRRHDSVENSDSHV 1174 MDUB7 SPREAP- -SLAVP ΞRH QEK--ALSVQDSSHSLPERFHEHKSVKSRKRRYETLE NDGRL 1182 ****** .

HDUB7 EKKARRSΞQ DPLEΞPKAKKHKKSKKKKKSKDKHRDRDSRHQQDSDLSAACSDADLHRHK 1234 MDUB7 EKKVHKSLEKDTLEΞPRVKKHKKS KKKKSKDKHRDRESRHQQESDFSGAYSDADLHRHR 1242 *** . : : * _;** _# ** ** ; _ι ******************* ****** .** . * _β * ******** ;

HDUB7 KKKK KKRHSR SEDFVKDSΞLHLPRVTSLETVAQFRRAQGGFPLSGGPP EGVGPFREK 1294 MDUB7 KKKKKK RHSRKSEDFIKDVΞMR PKLSSYEAGGHFRRTEGSF ADGLPVEDSGPFREK 1302

****************_*** *..**...* *. •***..* * *. * *.* ******

HDUB7 TKH RMESRDDRCRLFEYGQGD-- 1316 MDUB7 TKHLRMESRPDRCRLSEYGQDSTF 1326

********* ***** **** Table 17. Amino acid sequence alignment of catalytic domain among murine DUBl, DUB2, hDUB7 and n DUB7. Amino acids that are involved in catalysis in DUBl (Cys-60, Asp-133, and His-307) are underlined.

DUBl MWALSFPEADPA SSPDAPELHQDEAQWEELTVNGKHSLSWESPQGPGCG QNTGNSC 60 mDUB2 MWSLSFPEADPALSSPGAQQLHQDEAQWVE TA DKPSLSWECPQGPGCGLQNTGNSC 60 hDUB7 WYSSSSVPDKSKPSPQKDQALGDGIAPPQKVLFPSEKICLKWQQTHRVGAGLQN GNTC 120 mDUB7 WYSNSSVPEKSKPSPP DQVLGDGIAPPQKVLFPSEKICLK QQSHRVGAGLQNLGNTC 119

* **** **.* mDUBl Y NAALQCLTHTPPLADYM SQEHSQTCCSPEGCKLCAMEALVTQS LHSHSGDVMKPSH 120 mDUB2 YLNAALQCLTHTPP ADYMLSQEYSQTCCSPEGCKMC-MEAHVTQSLLHSHSGDVMKPSQ 120 hDUB7 FA AALQC TYTPPLA YM SHEHSKTCHAEGFCMMCTMQAHITQALSN- -PGDVI PMF 178 mDUB7 FANAALQCLTYTPPLA-.YMLSHEHSKTCHAEGFCMMCTMQTHITQALSN--PGDVIKPMF 177 . ********.*****.****.*.*.** - * :*_;*:: _;**_;* _; _***.** mDUBl ILTSA FH HQQEDAHEFLMFTLETMHESC QVHRQSKPTSEDSSPIHDIFGG W 174 mDUB2 ILTSA FHKHQQEDAHEFLMFTLETMHESC QVHRQSEPTΞEDSSPIHDIFGGL 174 hDUB7 VINEMRRIARHFRFGNQEDAHEF QYTVDAMQKACLNGSNKLDRHTQATT VCQIFGGYL 238 mDUB7 VINΞMRRIARHFRFGNQEDAHEFLQYTVDAMQKACLNGSNKLDRHTQATT VCQIFGGY 237

• ******** mDUBl RSQIKC CQGTSDTYDRFLDIP DISSAQSVKQA DTΞKSEE CGDNAYYCGKCRQ-M 234 mDUB2 RSQIKCLHCQGTSDTYDRFLDVPLDISSAQSV QALWDTEKSEELRGENAYYCGRCRQKM 234 hDUB7 RSRVKCLNCKGVSDTFDPYLDITLEIKAAQSVNKALEQFVKPEQLDGENSYKCSKCKKMV 298 mDUB7 RSRVKCLNCKGVSDTFDPY DITLEIKAAQSVTKALEQFVKPEQ DGENSYKCSKCKKMV 297

mDUBl PASKTL-WHIAPKVLMλTV- NRFSAFTGNKLDRKVSYPEF DLKPYLSEPTGGP PYALYA 294 mDUB2 PASKT HIHSAPKVLLLVLKRFSAFMGNKLDRKVSYPEFLDLKPYLSQPTGGPLPYALYA 294 hDUB7 PASKRFTIHRSS V TLSLKRFANFTGGKIAKDVKYPEY DIRPYMSQPNGEPIVYV YA 358 mDUB7 PASKRFTIHRSSNV TISLKRFANFTGGKIAKDVKYPEYLDIRPYMSQPNGEPIIYVLYA 357

**** . .* . .** . *.**. * * *. . * ***.**..**.*.* * *. * *** mDUBl V VHDGATSHSGHYFCCVKAGHGKWYKMDDTKVTRCDVTSVLNENAYVLFYVQQANLKQ 352 mDUB2 VLVHEGATCHSGHYFSYVKARHGA YKMDDTKVTSCDVTSVLNENAYVLFYVQQTDLKQ 352 hDUB7 V VHTGFNCHAGHYFCYIKASNGL YQMNDSIVSTSDIRSV SQQAYVLFYIRSHDVKN 417 mDUB7 VLVHTGFNCHAGHYFCYIKASNG YQM DSIVSTSDIRAVLNQQAYVLFYIRSHDVKN 416

**** *

Claims

What is claimed is:

1. An isolated polynucleotide encoding a human deubiquitinating protease selected from the group consisting of hDUB7 and mDUB7.

2. A polypeptide encoding a human deubiquitinating protease selected from the group consisting of lιDUB7 and mDUB7.

3. A method of using a polynucleotide according to claim 1, wherein the polynucleotide is used in an assay to identify an inhibitor of a hDUB or mDUB7 of claim 1.

4. A method of using a polypeptide according to claim 2, wherein the polypeptide is used in an assay to identify an inhibitor of a hDUB or mDUB7 of claim 2.

« 5. A method of reducing inflammation by regulating proinflammatory cytokine signaling, by administering a compound capable of inhibiting a polypeptide according to claim 2.

6. A method of modulating an autoimmune disease by altering cytokine receptor signaling involved in lymphocytes proliferation, by administering a compound capable of inhibiting a polypeptide according to claim 2.

7. A method of modulating an immune reaction during infection, by administering a compound capable of inhibiting a polypeptide according to claim 2.

8. A method of reducing inflammation by regulating proinflammatory cytokine signaling, by administering a compound capable of altering regulation of transcription of a polynucleotide of claim 1.

9. A method of modulating an autoimmune disease by altering cytokine receptor signaling involved in lymphocytes proliferation, by administering a compound capable of altering regulation of transcription of a polynucleotide of claim 1.

10. A method of modulating an immune reaction during infection, by administering a compound capable of altering regulation of transcription of a polynucleotide of claim 1.

11. A method of identifying a modulator of a human deubiquitinating protease, wherein a compound is added to the reporter assay comprising a polynucleotide immediately 5' to a human deubiquitinating protease selected from the group consisting of hDUB7 and mDUB7 operatively linked to a reporter gene, and the effect of the compound is determined.

12. A transducing peptide comprising an NLS or transducing sequence of hDUB7 or mDUB7 linked to a cargo molecule.

13. The transducing peptide of claim 12, wherein the NLS or tr-ansducing sequence is selected from the group consisting of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.

14. The transducing peptide of claim 12, wherein the cargo molecule is a biologically active protein, therapeutically effective compound, antisense nucleotide, or test compound.

15. A method of delivering a biologically active protein, therapeutically effective compound, antisense nucleotide, or test compound to a cell wherein a transducing peptide of claim 12 is added exogenously to a cell.